

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Patient-Centered Care for Addictions Treatment: A Scoping Review Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024588
Article Type:	Protocol
Date Submitted by the Author:	03-Jun-2018
Complete List of Authors:	Marchand, Kirsten; University of British Columbia, School of Population and Public Health; Centre for Health Evaluation and Outcome Sciences, Beaumont, Scott; University of British Columbia, School of Population and Public Health; Centre for Health Evaluation and Outcome Sciences, Westfall, Jordan; Canadian Association for People Who Use Drugs MacDonald, Scott; Providence Health Care, Crosstown Clinic Harrison, Scott; Providence Health Care, Crosstown Clinic Marsh, David; Northern Ontario School of Medicine, Schechter, Martin; University of British Columbia, SPPH; Centre for Health Evaluation and Outcome Sciences, Oviedo-Joekes, Eugenia; University of British Columbia, School of Population and Public Health; Centre for Health Evaluation and Outcome Sciences,
Keywords:	Patient-centered care, Client-centered care, Substance-related disorders, Problematic substance use, Addiction treatment

SCHOLARONE™
Manuscripts

Only

Patient-Centered Care for Addictions Treatment: A Scoping Review Protocol

Authors:

Kirsten Marchand^{1,2}

Scott Beaumont¹

Jordan Westfall³

Scott MacDonald⁴

Scott Harrison⁴

David C. Marsh⁵

Martin T. Schechter^{1,2}

Eugenia Oviedo-Joekes^{1,2}

Author affiliation and addresses:

1. School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC, V6T 1Z3, Canada.
2. Centre for Health Evaluation & Outcome Sciences, Providence Health Care, St. Paul's Hospital, 575- 1081 Burrard St., Vancouver, BC, V6Z 1Y6, Canada.
3. Canadian Association for People Who Use Drugs, 46 East Hastings St., Vancouver, BC V6A 1N1, Canada.
4. Providence Health Care, Providence Crosstown Clinic, 84 West Hastings St., Vancouver, BC V6B 1G6, Canada.
5. Northern Ontario School of Medicine, 935 Ramsey Lake Road, Sudbury, ON P3E 2C6, Canada.

Corresponding Author:

Kirsten Marchand

575-1081 Burrard St., Vancouver, BC, V6Z 1Y6, Canada.

kmarchand@cheos.ubc.ca

778-847-8715

Word count (excluding title page, abstract, references, figures and tables): 2,915

Keywords: Patient-centered care; client-centered care; addiction treatment; substance-related disorders; problematic substance use

ABSTRACT:

Introduction: Substance use disorders are chronic conditions that may benefit from expanded person-focused treatment approaches. Patient-centered care (PCC), commonly used for chronic conditions, is a structured treatment approach that responds to patients' unique needs and has been associated with positive outcomes (e.g., treatment retention, health outcomes). Despite its demonstrated effectiveness, evidence regarding its feasibility and potential outcomes among people with substance dependence remain limited. The aim of this scoping review is to explore how patient-centered care has been defined, measured and implemented among people with problematic substance use.

Methods and analysis: This scoping review follows the iterative stages of the Arksey and O'Malley framework. Both empirical (from Medline, Embase, PsycINFO, CINAHL and ISI Web of Science) and grey literature references will be considered if they focused on populations with problematic substance use and described or measured PCC or one of its components in a health-oriented context. Two reviewers will independently screen and review references. A descriptive overview, numerical summaries (where relevant) and a directed content analysis will be carried out on extracted data. This scoping review will be registered with Open Science Framework.

Ethics and dissemination: This review will generate evidence to inform decision-makers and health care providers on the feasibility, implications and potential outcomes associated with PCC for substance use treatment. A multidisciplinary team has been gathered to represent the needs of people with problematic substance use, health care providers and decision makers. The team's knowledge users will be engaged throughout this review and will participate in dissemination activities (e.g., workshops, presentations, publications, reports).

ARTICLE SUMMARY: (Strengths and Limitations of this Study)

- This is the first scoping review to systematically explore how patient-centered care has been defined, measured and implemented among people with problematic substance use.
- A multidisciplinary team composed of drug policy advocates, health care providers, decision makers and academics will lead this scoping review.
- Both the population (people with problematic substance use) and concept of interest (patient-centered care) have been indexed using a variety of terms, which poses a challenge to ensuring breadth of the search.
- A comprehensive search strategy has been developed in consultation with a health sciences librarian to promote a sensitive scope of empirical and grey literature sources.
- This iterative scoping review study has been registered with Open Science Framework to enhance its transparency.

1. INTRODUCTION

Alcohol, tobacco and illicit substance use is a significant public health concern that accounts for 11.2% of the global burden of disease and 21.1% of all deaths.[1] People with substance use disorders are at an increased risk of mortality and morbidity;[2, 3] and some may be further affected by lost family and social support, criminal justice involvement, and social marginalization.[4] These associated harms highlight the multi-factorial nature of substance use disorders.[5, 6]

This multi-factorial nature, combined with the fact that drugs are subject to inconsistent policies (i.e., some are illegal, some are not),[7, 8] and affect the brain and body differently,[9] add to the complexity of its treatment. Effective pharmacological therapies are available to assist with the treatment of some, but not all, substance use disorders. For instance, for opioid use disorder, medication assisted treatment (e.g., oral methadone) has shown to be the most effective approach to reduce the use of illicit opioids and its associated harms.[10] On the other hand, psychosocial interventions (e.g., cognitive behavioural therapy; contingency management) can be very effective.[11-13] However, these approaches can be limited in their effectiveness at engaging and treating some populations (e.g., people with opioid use disorder or with severe mental comorbidities).[12-14] Both pharmacological and psychosocial interventions can be offered in a variety of settings (e.g., residential, community-based outpatient), delivered by different health care professionals (e.g., nurses, counselors, physicians), and with a wide range of outcome expectations (e.g., abstinence-oriented, harm reduction).[6, 15]

Despite variability in the settings, providers and expectations of substance use treatment, interventions are recommended to adopt a chronic, recovery-oriented approach,[16, 17] and one that adapts to the unique, person-specific, treatment needs.[6, 18] Indeed, evidence has shown that when clients' needs (e.g., housing, parenting support, medical care) are matched to the services offered, they are more likely to be retained to substance use treatment.[19-21] Patient-centered care (PCC) is a structured approach that encompasses these recommendations by prioritizing clients' unique goals, values, and involvement in the treatment and recovery process. As such, PCC warrants further consideration for efforts aimed at optimizing the responsiveness of substance use treatment to the individualized and long-term needs of its clients.

PCC has a longstanding history in clinical psychology, and has emerged in medicine over the past decade in efforts to improve the quality and effectiveness of health care, particularly for people with chronic illnesses.[22-24] This is not surprising, since research has shown PCC to be associated with treatment retention and adherence, treatment satisfaction, improved health outcomes, and quality of life.[23-25] The most common principles, as defined in concept analyses[26, 27] and reviews in the health sciences literature[24, 28, 29] are: (1) *understanding the whole person* to account for the biological, psychological and social aspects of patients' illnesses (i.e., holistic or comprehensive care); (2) *exploring the disease and illness experience* to understand the personal meaning of illness for the patient (i.e., person-focused or individualized care); (3) *finding common ground* where power, knowledge and responsibility are shared

1
2
3 between the patient and provider (i.e., shared-decision making or collaborative care); and (4)
4 *enhancing the patient-provider relationship* to improve the positive outcomes of treatments
5 provided (i.e., relational care).
6

7
8 For people with substance use disorders, research to date has focused on measuring specific
9 principles or concepts that broadly overlap with PCC, such as individualized treatment
10 preferences, needs and goals,[19, 30, 31] shared-decision making[32] or client autonomy[33] and
11 relational care.[34, 35] These studies have been conducted with specific populations of people
12 with substance use disorders (e.g., for people with primarily alcohol or opioid use disorder).
13 However, the PCC principles that have been applied in this broad evidence base could be
14 adapted into a variety of treatments and settings, which could yield significant opportunities that
15 improve the quality of treatments for people with substance use disorders.
16
17

18
19 To begin considering the potential benefits of PCC for people with substance use disorder, a
20 comprehensive review of the existing evidence and grey literature is needed to gain initial
21 understanding of what aspects of PCC have been empirically tested and clinically adopted.
22 Bringing this evidence together in a systematic scoping review has the potential to inform future
23 research and policy efforts aimed at designing and testing the effectiveness of a structured PCC
24 approach for the treatment of substance use disorders. To our knowledge, no such review is
25 currently available.
26
27

28 29 **2. OBJECTIVE**

30
31 The present scoping review will systematically explore how patient-centered care has been
32 defined, measured and implemented in health care settings for people with substance use
33 disorders. Specifically, this review aims to examine the extent and nature of existing evidence of
34 PCC in addiction research and clinical practice. This review will generate evidence to inform
35 future directions for research and clinical practice design.
36
37

38 39 **3. METHODS AND ANALYSIS**

40
41 This scoping review methodology will adopt the classic framework developed by Arksey and
42 O'Malley,[36] and recent enhancements[37, 38, 39] including best practices for conducting and
43 reporting systematic reviews (i.e., Preferred Reporting Items for Systematic Review and Meta-
44 Analysis (PRISMA) or PRISMA for scoping reviews once available).[39-41] Accordingly, a
45 reflexive and iterative approach will be maintained; particularly during the study selection and
46 data extraction phases, which may become more refined throughout the review. All iterations of
47 the protocol will be registered through Open Science Framework.[42] DistillerSR software for
48 systematic reviews[43] will be used by both reviewers for screening, extraction, monitoring and
49 to support synthesis and summarizing of findings.
50
51

52 53 **3.1. Stage 1: Defining the Research Question**

54
55
56
57
58

1
2
3 The research question was developed as a broad framing of the population (i.e., people with
4 problematic substance use), the concept (i.e., patient-centered care) and the context (i.e., health-
5 oriented settings) to be explored. Thus, this scoping review asks:
6

- 7 1. What patient-centered care principles and outcomes have been empirically explored and
8 implemented in health-oriented settings for people with problematic substance use?
9

10 11 **3.2. Stage 2: Identifying Relevant Literature**

12 Our goal in developing this search strategy is to undertake a comprehensive review of the
13 existing evidence base. However, this particular research question poses a challenge to keyword
14 selection due to the evolution of terms used to describe both the population and concept of
15 interest. For instance, problematic substance use has grown from the pejorative language of the
16 ‘addict’ to a health-oriented view of ‘substance dependent populations’ and now onto the more
17 person-focused discourse of ‘people with problematic substance use’.[44, 45] Likewise, patient-
18 centered care has also been indexed using a variety of terms reflecting its progression from
19 psychology (i.e., ‘client centered therapy’, ‘person-focused care’) to its recent arrival in medicine
20 (i.e., ‘patient-centered care’). Adding to this complexity, specific PCC principles such as
21 ‘collaborative care’, and ‘whole-person’ care have also been reported.[27, 29] To overcome this
22 sensitivity-related challenge, we have engaged in an extensive consultation process with an
23 experienced Health Science Librarian (at the University of British Columbia) as well as the
24 knowledge users represented in our team (authors SM and SH). The search strategy will also be
25 peer reviewed (i.e., PRESS) to promote its rigor and feasibility.[46]
26

27 Given our interest in undertaking a comprehensive review of existing research and clinical
28 guidelines related to PCC in the addictions field, both empirical (primary studies, previous
29 reviews), and grey literature documents (conference abstracts, reports and clinical guidelines)
30 will be included in our search. The search for empirical sources will be conducted in the most
31 important electronic databases for the medical and social sciences: Medline (Ovid), Embase
32 (Ovid), PsycINFO, CINAHL and ISI Web of Science. The search strategy will be developed in
33 Medline (Ovid), will undergo PRESS, and will then be adapted to the other databases. The
34 search strategy will include subject headings, related terms, and keywords as necessary for the
35 research question. Boolean logic and operators (i.e., ‘and’, ‘or’, ‘not’) will be used to combine
36 search terms and concepts.
37

38 For the grey literature search strategy, we will utilize recommended resources[47] and consult
39 with the Health Sciences Librarian and our team’s knowledge users to devise a database specific
40 approach. The search for abstracts, reports and clinical guidelines will be carried out in several
41 Canadian-specific databases: British Columbia Guidelines and Protocols Databases, CPG
42 Infobase, the Registered Nurses’ Association Clinical Practice Guidelines Program, and Des
43 Libris. For international grey literature documents, we will search National Guideline
44 Clearinghouse, TRIP, Google and Google Scholar databases.
45

46 47 **3.3. Stage 3: Study Selection**

1
2
3 A two-stage collaborative review process will be used to select references. Eligibility criteria
4 have been developed *a priori*, in consultation with the study team. The screening form will be
5 piloted on the first 20 citations of the initial Medline (Ovid) search to test both the criteria and
6 reviewer agreement. Two independent reviewers (authors KM and SB) will apply eligibility
7 criteria during the initial title/abstract review. After each review stage, the reviewer's agreement
8 will be assessed and a third reviewer (author EOJ) will be consulted in cases of disagreement,
9 until consensus is achieved.

10
11
12 A title/abstract (or executive summary for reports and guidelines) will be eligible for full text
13 screening if it:

14
15
16 a) Referred to people with problematic substance use (including tobacco, alcohol, cannabis,
17 stimulant or opioid use);

18
19 b) Was about delivering patient-centered care or one of its components (including collaborative
20 care, comprehensive care, care that enhances the patient-provider relationship, and care that
21 attends to personal meaning of illness and recovery); and

22
23 c) Was set in a health-oriented context (including inpatient or outpatient hospital settings,
24 emergency departments, community-based or primary care health settings, and any specialized
25 drug treatment or low-threshold agencies and programs; excluding prison-based health programs
26 and self-help models such as narcotics or alcoholics anonymous);

27
28
29 d) Was published between January 1, 1960 and March 1, 2018 in English, French, Spanish,
30 Italian, Portuguese and German.

31
32 Full text empirical articles, reports and guidelines will then be obtained for titles/abstracts
33 meeting these above criteria and will undergo further screening. In addition to the title/abstract
34 criteria, full texts will be included in the review if:

35
36
37 e) It provided an operational definition of the patient-centered care framework that was delivered
38 to people with problematic substance use in the health-oriented context; and

39
40 f) It observed at least one outcome (e.g., treatment compliance, treatment satisfaction) of the
41 patient-centered treatment approach (this criterion pertains to empirical articles only).

42
43 As such, articles that provide only a recommendation to adopt PCC or an opinion of how PCC
44 should be implemented in health-oriented settings for people with problematic substance use will
45 not be included.

46 47 48 **3.4. Stage 4: Data Extraction**

49
50 Results of the search will be collated in DistillerSR,[43] allowing the research team to de-
51 duplicate and perform data extraction. We will follow recommended data charting methods[36,
52 41] to systematically capture relevant details for studies/reports and guidelines (Table 1). Data
53 charting forms will be piloted with the first 5 empirical and grey literature references and may be
54 adapted thereafter (with input from the teams' knowledge users).

Table 1. Data extraction and charting for empirical and grey literature sources

Domain/Subdomain	Description
1. General Document Details	
1.1 Reference Type	Empirical study, case study, review, commentary, report, guideline
1.2 Publication Year	Year of publication
1.3 Country and Location	Country of publication (and location if provided)
1.4 Publication Language	Language of publication
2. Empirical Study References (if applicable)	
2.1 Research objective	What was the research objective or specific question to be tested (if relevant)
2.2 Study design	Was the study design observational, experimental or qualitative?
2.3 Study population	What were the eligibility criteria? Would the population be classified as primarily: tobacco, cannabis, alcohol, opioid, stimulant or comorbid substance use and mental illness?
2.4 Patient-centered care intervention	What was the operational definition of patient-centered care used (including the definition of specific principles, if available)? How long was the intervention provided or observed for?
2.5 Context/setting	What health-oriented context was the PCC intervention apart of? What health professionals were involved?
2.6 Study outcomes	For quantitative studies, what were the primary and secondary outcomes measured? For qualitative studies, what outcomes were described?
2.7 Important results	What were the main results of the study? Were there any important sub-group analyses (e.g., by sex and gender, by primary substance, by health care provider)?
2.8 Limitations	What limitations did the authors describe? What others might there be?
3. Grey Literature References (if applicable)	
3.1 Target audience	Is there a target audience specified for the guideline/report (e.g., policy/decision maker, health care provider, patient/client/family)
3.2 Reference population	If available, how was the target patient population defined? Any specific eligibility criteria used? Would the population be classified as primarily: tobacco, cannabis, alcohol, opioid, stimulant or comorbid substance use and mental illness?
3.3 Patient-centered care operational definition	What was the operational definition of patient-centered care used (including the definition of specific principles, if available)?
3.4 Context/setting	What health-oriented context was the PCC intervention apart of? What health professionals were involved?

3.5 Intervention and outcomes	If applicable, was a specific patient-centered intervention described (e.g., a training module, a clinical approach)? Were any outcomes reported (e.g., patient or provider satisfaction)?
3.6 Program evaluation	If available, results of any ongoing program evaluations?

3.5. Stage 5: Collating, Summarizing and Reporting the Results

We will present a descriptive overview (including numerical summaries; e.g., effect size if available) of the eligible full texts.[36] In addition to basic tables and charts of the studies and guidelines, we will also summarize studies by each broader category of substances primarily used (i.e., tobacco, cannabis, alcohol, opioid, or stimulant). Displaying information in this way will enhance understanding of population-specific similarities and differences in the patient-centered approach, its definition and outcomes. This will greatly facilitate the identification of future directions for research and practice. All tables and charts will include narrative summaries, relating the findings to the review's research question. Additionally, we will develop a final report of the review,[41] according to relevant aspects of the PRISMA guidelines.[39]

Given that this review aims to understand *how* PCC has been implemented in health care services for people with problematic substance use, a directed content analysis will be carried out on included guidelines. Specifically, we are interested in qualitatively analyzing the definition of PCC adopted in the guidelines, how they were developed, what health care providers were involved, and any outcomes or ongoing evaluations of the program. To do so, data from the guidelines will be imported to MAXQDA, version 12,[48] a qualitative analysis software program that supports a multi-user approach. This analysis will be conducted by authors KM, SB and EOJ, who have prior experience conducting thematic analysis on similar topics.[49, 50] As is common in directed content qualitative analysis,[51] a coding framework will be developed a priori, and will be applied by authors KM and SB independently. Results from this analysis will be summarized and where relevant numerical summaries may also be used to provide additional context to the themes (e.g., number of clients treated, number of staff).

3.6. Stage 6: Consultation Process and Engagement of Knowledge Users

The ultimate aim of this review is to generate evidence that can be used to inform decision-makers and health care providers on the feasibility, implications and potential outcomes associated with PCC for substance use treatment. To achieve this goal, we have engaged a multi-disciplinary team of knowledge users who represent the needs of people with problematic substance use, health care providers and decision makers. This team will be engaged at each stage of the project to discuss and refine eligibility criteria, data extraction and analysis. For example, our team's drug policy knowledge user (author JW) represents a national organization of people who use drugs and will contribute this critical perspective to ensure that all aspects of this review are rooted in the client-centered needs of this diverse population. Similarly, consulting with the team's health care providers (authors SM and SH) and decision-makers

(authors SH and DCM) will promote a methodology that reflects the realities of patient-provider roles and the health care system's organization. Lastly, through this team's diverse network, there will also be opportunities to disseminate findings directly to patients, health care providers, decision makers and drug policy experts. The planned consultation process will therefore empower knowledge users with a broad understanding of how PCC has been conceptually defined and its potential for improving health care outcomes among people with problematic substance use.

4. DISCUSSION

As substance use disorders are increasingly recognized as chronic and relapsing conditions, the public health care system is considering how existing treatment and intervention approaches can be optimized to meet the long-term and evolving goals of clients.[18] A structured patient-centered approach may be one such opportunity. To our knowledge, this review will be the first to systematically examine the extent and nature of existing evidence of PCC in addiction research and clinical practice.

By taking into account both empirical and grey literature from the broader field of addictions, we will gain a comprehensive understanding of how PCC has been defined, measured and implemented. Specifically, empirical literature will provide evidence regarding the possible outcomes of PCC and grey literature (especially the reports and guidelines) will yield evidence informing how PCC has already been implemented in the various health-oriented contexts. Together, this evidence will inform the development of a consistent operational definition of PCC, which is needed for future standardization in clinical practice and ongoing measurement. Additionally, bringing this evidence together will provide a deeper understanding of the value that particular principles bring to treatment outcomes. For example, across populations and settings, we might find that shared-decision making is particularly beneficial for pharmacological medication adherence, while whole-person care improves health and social outcomes. These combined findings will provide a description of how PCC could be defined, implemented and tested. Such evidence is critical to offering clients the opportunity to participate in treatment that is comprehensive, individualized and empowering.

AUTHOR CONTRIBUTIONS:

KM (review guarantor) led the design and conceptualisation of this review and drafted the protocol with primary support from SB and EOJ. SB, SH, and EOJ were involved in refining the search strategy, including key words. SM, SH, and JW, were involved in establishing eligibility criteria and data extraction forms. All authors provided feedback on the manuscript and approval to the publishing of this protocol manuscript.

AMENDMENTS: Not applicable

1
2
3 **SUPPORT (SOURCES, SPONSOR, ROLE OF SPONSOR OR FUNDER):** Funding for this
4 scoping review has been provided by the Canadian Institutes of Health Research (Operating
5 Grant: Opioid Crisis Knowledge Synthesis). We would also like to acknowledge Ursula Ellis,
6 Health Sciences Librarian (University of British Columbia), who has provided invaluable
7 expertise to the search strategy of this scoping review.
8
9

10
11 **COMPETING INTERESTS:** The authors have no competing interests to declare.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

References

- 1 Gakidou E, Afshin A, Abajobir AA, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. *The Lancet* 2017;390:1345-422. doi: 10.1016/S0140-6736(17)32366-8
- 2 Holford TR, Meza R, Warner KE, et al. Tobacco control and the reduction in smoking-related premature deaths in the united states, 1964-2012. *JAMA* 2014;311(2):164-71. doi: 10.1001/jama.2013.285112
- 3 Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. *Lancet* 2013;382:1575-86. doi: 10.1016/s0140-6736(13)61611-6 [published Online First: 2013/09/03]
- 4 Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. *Lancet* 2010;376:1558-65. doi: [http://dx.doi.org/10.1016/S0140-6736\(10\)61462-6](http://dx.doi.org/10.1016/S0140-6736(10)61462-6)
- 5 American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). Arlington, VA: American Psychiatric Publishing; 2013.
- 6 United Nations Office on Drugs and Crime. World Drug Report 2015. United Nations publication 2015.
- 7 Pompidou Group. Policy paper providing guidance to policy makers for developing coherent policies for licit and illicit drugs. Strasbourg: Council of Europe; 2011.
- 8 United Nations Office on Drugs and Crime (UNODC). World Drug Report 2017. United Nations publication 2017.
- 9 Egervari G, Ciccocioppo R, Jentsch JD, et al. Shaping vulnerability to addiction - the contribution of behavior, neural circuits and molecular mechanisms. *Neurosci Biobehav Rev* 2018;85:117-25. doi: 10.1016/j.neubiorev.2017.05.019 [published Online First: 2017/06/03]
- 10 Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. *Cochrane Database Syst Rev* 2009;2:1-34.
- 11 Fischer B, Blanken P, Da Silveira D, et al. Effectiveness of secondary prevention and treatment interventions for crack-cocaine abuse: a comprehensive narrative overview of English-language studies. *Int J Drug Policy* 2015;26:352-63. doi: 10.1016/j.drugpo.2015.01.002 [published Online First: 2015/02/11]
- 12 Jhanjee S. Evidence Based Psychosocial Interventions in Substance Use. *Indian Journal of Psychological Medicine* 2014;36:112-18. doi: 10.4103/0253-7176.130960

- 1
2
3 13 Magill M, Ray LA. Cognitive-Behavioral Treatment With Adult Alcohol and Illicit Drug
4 Users: A Meta-Analysis of Randomized Controlled Trials. *Journal of Studies on Alcohol and*
5 *Drugs* 2009;70:516-27. doi: 10.15288/jsad.2009.70.516
6
7
8 14 Hunt GE, Siegfried N, Morley K, et al. Psychosocial interventions for people with both
9 severe mental illness and substance misuse. *Schizophr Bull* 2014;40:18-20. doi:
10 10.1093/schbul/sbt160 [published Online First: 2013/11/02]
11
12 15 Sumnall HR, Bates, G., Jones, L. Evidence review summary: drug demand reduction,
13 treatment and harm reduction. In: European Monitoring Centre for Drugs and Drug
14 Addiction, ed. Health and social responses to drug problems: a European guide. United
15 Kingdom 2017.
16
17
18 16 McLellan AT, McKay JR, Forman R, et al. Reconsidering the evaluation of addiction
19 treatment: from retrospective follow-up to concurrent recovery monitoring. *Addiction*
20 2005;100:447-58. doi: 10.1111/j.1360-0443.2005.01012.x [published Online First:
21 2005/03/24]
22
23
24 17 Recovery Orientated Drug Treatment Expert Group. Medications in Recovery: Re-
25 orienting Drug Dependence Treatment. London, UK: National Treatment Agency for
26 Substance Misuse 2012.
27
28
29 18 European Drug Monitoring Centre for Drugs and Drug Addiction. Health and social
30 responses to drug problems: a European guide. Luxembourg: Publications Office of the
31 European Union 2017.
32
33
34 19 Hser YI, Polinsky ML, Maglione M, et al. Matching clients' needs with drug treatment
35 services. *J Subst Abuse Treat* 1999;16:299-305. [published Online First: 1999/06/01]
36
37 20 Friedmann PD, Hendrickson JC, Gerstein DR, et al. The effect of matching comprehensive
38 services to patients' needs on drug use improvement in addiction treatment. *Addiction*
39 2004;99:962-72. doi: 10.1111/j.1360-0443.2004.00772.x [published Online First:
40 2004/07/22]
41
42 21 Marsh JC, Cao D, Shin HC. Closing the Need-Service Gap: Gender Differences in Matching
43 Services to Client Needs in Comprehensive Substance Abuse Treatment. *Social work*
44 *research* 2009;33:183-92. [published Online First: 2009/09/01]
45
46
47 22 Beaulieu MD. President's message: toward a patient-centred health care system. *Can*
48 *Fam Physician* 2013;59:109,10. [published Online First: 2013/01/24]
49
50 23 Epstein RM, Fiscella K, Lesser CS, et al. Why the nation needs a policy push on patient-
51 centered health care. *Health Aff (Millwood)* 2010;29:1489-95. doi:
52 10.1377/hlthaff.2009.0888 [published Online First: 2010/08/04]
53
54
55
56
57
58

- 1
2
3 24 McMillan SS, Kendall E, Sav A, et al. Patient-centered approaches to health care: a
4 systematic review of randomized controlled trials. *Medical care research and review: MCRR*
5 2013;70:567-96. doi: 10.1177/1077558713496318 [published Online First: 2013/07/31]
6
7 25 Stewart M, Brown JB, Donner A, et al. The impact of patient-centered care on outcomes. *J*
8 *Fam Pract* 2000;49:796-804. [published Online First: 2000/10/14]
9
10 26 Slater L. Person-centredness: a concept analysis. *Contemp Nurse* 2006;23(1):135-44.
11 doi: 10.5555/conu.2006.23.1.135 [published Online First: 2006/11/07]
12
13 27 Morgan S, Yoder LH. A concept analysis of person-centered care. *J Holist Nurs*
14 2012;30:6-15. doi: 10.1177/0898010111412189 [published Online First: 2011/07/21]
15
16 28 Hudon C, Fortin M, Haggerty JL, et al. Measuring patients' perceptions of patient-
17 centered care: a systematic review of tools for family medicine. *Ann Fam Med* 2011;9:155-
18 64. doi: 10.1370/afm.1226 [published Online First: 2011/03/16]
19
20 29 Mead N, Bower P. Patient-centredness: a conceptual framework and review of the
21 empirical literature. *Soc Sci Med* 2000;51:1087-110. [published Online First: 2000/09/27]
22
23 30 Uebelacker LA, Bailey G, Herman D, et al. Patients' beliefs about medications are
24 associated with stated preference for methadone, buprenorphine, naltrexone, or no
25 medication-assisted therapy following inpatient opioid detoxification. *Journal of substance*
26 *abuse treatment* 2016;66:48-53. doi: 10.1016/j.jsat.2016.02.009
27
28 31 Joosten EAG, De Weert-Van Oene GH, Sensky T, et al. Treatment Goals in Addiction
29 Healthcare: the Perspectives of Patients and Clinicians. *International Journal of Social*
30 *Psychiatry* 2010;57:263-76. doi: 10.1177/0020764009354835
31
32 32 Joosten EA, De Jong CA, de Weert-van Oene GH, et al. Shared decision-making: increases
33 autonomy in substance-dependent patients. *Subst Use Misuse* 2011;46:1037-8. doi:
34 10.3109/10826084.2011.552931 [published Online First: 2011/03/05]
35
36 33 Schwartz RP, Kelly SM, Mitchell SG, et al. Patient-Centered Methadone Treatment: A
37 Randomized Clinical Trial. *Addiction* 2016 doi: 10.1111/add.13622 [published Online First:
38 2016/09/24]
39
40 34 Joosten E, de Weert G, Sensky T, et al. Effect of shared decision-making on therapeutic
41 alliance in addiction health care. *Patient Prefer Adherence* 2008;2:277-85. [published
42 Online First: 2008/01/01]
43
44 35 Meier PS, Barrowclough C, Donmall MC. The role of the therapeutic alliance in the
45 treatment of substance misuse: a critical review of the literature. *Addiction* 2005;100:304-
46 16.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 36 Arksey H, O'Malley L. Scoping studies: towards a methodological framework.
4 *International Journal of Social Research Methodology* 2005;8:19-32. doi:
5 10.1080/1364557032000119616
6
7 37 Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology.
8 *Implementation Science* 2010;5:69. doi: 10.1186/1748-5908-5-69
9
10 38 Daudt HM, van Mossel C, Scott SJ. Enhancing the scoping study methodology: a large,
11 inter-professional team's experience with Arksey and O'Malley's framework. *BMC Medical*
12 *Research Methodology* 2013;13:48. doi: 10.1186/1471-2288-13-48
13
14 39 Colquhoun HL, Levac D, O'Brien KK, et al. Scoping reviews: time for clarity in definition,
15 methods, and reporting. *J Clin Epidemiol* 2014;67:1291-4. doi:
16 10.1016/j.jclinepi.2014.03.013 [published Online First: 2014/07/19]
17
18 40 Tricco A, Straus, S., Moher, D. Preferred reporting items for systematic reviews and
19 meta-analysis: extension for Scoping Reviews (PRISMA-ScR): EQUATOR Network;
20 Available from: [http://www.equator-network.org/wp-](http://www.equator-network.org/wp-content/uploads/2009/02/Executive-summary_ScR_Dec-9.pdf)
21 [content/uploads/2009/02/Executive-summary_ScR_Dec-9.pdf](http://www.equator-network.org/wp-content/uploads/2009/02/Executive-summary_ScR_Dec-9.pdf) (accessed November 22,
22 2017.)
23
24 41 Joanna Briggs Institute. The Joanna Briggs Institute Reviewers' Manual 2015:
25 Methodology for JBI Scoping Reviews. Australia 2015.
26
27 42 Center for Open Science. Open Science Framework Charlottesville, VA2011 [cited 2018].
28 Available from: <https://osf.io> (accessed May 7, 2018).
29
30 43 DistillerSR: Systematic Review and Literature Review Software [program]. Ottawa,
31 Canada: Evidence Partners, 2016.
32
33 44 Kelly JF, Saitz R, Wakeman S. Language, Substance Use Disorders, and Policy: The Need
34 to Reach Consensus on an "Addiction-ary". *Alcoholism Treatment Quarterly* 2016;34:116-
35 23. doi: 10.1080/07347324.2016.1113103
36
37 45 Broyles LM, Binswanger IA, Jenkins JA, et al. Confronting inadvertent stigma and
38 pejorative language in addiction scholarship: a recognition and response. *Subst Abus*
39 2014;35:217-21. doi: 10.1080/08897077.2014.930372 [published Online First:
40 2014/06/10]
41
42 46 McGowan J, Sampson M, Salzwedel DM, et al. PRESS Peer Review of Electronic Search
43 Strategies: 2015 Guideline Statement. *J Clin Epidemiol* 2016;75:40-6. doi:
44 10.1016/j.jclinepi.2016.01.021 [published Online First: 2016/03/24]
45
46 47 Canadian Agency for Drugs and Technologies in Health. Grey Matters: a practical tool for
47 searching health-related grey literature. [online resource]. 2015 Available from:
48 <https://www.cadth.ca/resources/finding-evidence/grey-matters> accessed November 22,
49 2017.
50
51
52
53
54
55
56
57
58

1
2
3 48 MAXQDA Qualitative Analysis Software, 2015.
4

5 49 Oviedo-Joekes E, Marchand K, Lock K, et al. A chance to stop and breathe: participants'
6 experiences in the North American Opiate Medication Initiative clinical trial. *Addiction*
7 *science & clinical practice* 2014;9:21-31. doi: 10.1186/1940-0640-9-21 [published Online
8 First: 2014/09/30]
9

10
11 50 Oviedo-Joekes E, Marchand K, Palis H, et al. Predictors of treatment allocation guesses in
12 a randomized controlled trial testing double-blind injectable hydromorphone and
13 diacetylmorphine for severe opioid use disorder. *Addiction Research & Theory*
14 2017;25:263-72. doi: 10.1080/16066359.2016.1263729
15

16
17 51 Hsieh H-F, Shannon SE. Three Approaches to Qualitative Content Analysis. *Qualitative*
18 *Health Research* 2005;15:1277-88. doi: 10.1177/1049732305276687
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplement Table: Ovid-Medline Search Strategy

Search number	Search term that entered to Ovid-Medline	No. of Hits ^a
1	exp Substance-Related Disorders	258404
2	exp Street Drugs	11238
3	substance abus*	49574
4	substance dependen*	2731
5	substance misus*	2166
6	Problematic substance adj2 (use* or usage or using)	254
7	(people who inject drug*) or PWID	1767
8	injection drug "(use or user or usage or using)" or IDU	2800
9	"people who use drugs" or PWUD	348
10	(illicit or street or illegal) adj2 (drug or substance) adj2 (use* or usage or using)	5855
11	opioid adj2 (addict* or abus* or dependen* or misus* or problem* or disorder*)	15436
12	opiate adj2 (addict* or abus* or dependen* or misus* or problem* or disorder*)	3474
13	narcotic adj2 (addict* or abus* or dependen* or misus* or problem* or disorder*)	1278
14	heroin	17876
15	"stimulant use disorder"	41
16	exp crack cocaine	1343
17	exp cocaine smoking	3
18	((cocaine or crack) adj2 (addict* or abus* or dependen* or misus* or problem* or disorder*))	11821

19	(amphetamine or crystal methamphetamine or crystal meth) adj1 (addict* or abus* or dependen* or misus* or problem* or disorder*)	591
20	alcohol adj2 (addict* or abus* or dependen* or misus* or problem* or disorder*)	50198
21	cannabis adj2 (addict* or abus* or dependen* or disorder*)	1917
22	(tobacco or nicotine or smok*) adj2 (dependen* or disorder* or cessation)	45596
23	Diagnosis, Dual (Psychiatry)	3378
24	1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23	337401
25	exp Patient-Centered Care	16521
26	((patient or client or person) adj1 cent?red adj1 (care or treatment* or therap*))	20613
27	((patient or client or person) adj1 focus?ed adj1 (care or treatment* or therap*))	425
28	Patient participation	22542
29	collaborative adj1 (care or practic* or treatment* or plan*)	3781
30	(shared or joint or collaborative) adj2 decision making	6241
31	Comprehensive health care	6395
32	Professional-Patient Relations	25040
33	therapeutic alliance	2068
34	relational practic*	45
35	(professional or physician or doctor or nurse or health professional or health provider) adj1 patient adj1 (relationship* or alliance*)	21872
36	(professional or physician or doctor or nurse or health professional or health provider) adj1 patient adj1 communication*	3015
37	Holistic Nursing	3453
38	trauma adj1 (cent?red or informed) adj1 (care or approach or treatment* or therap*)	262

39	cultural* adj1 (safe or sensitive) adj1 (care or approach or treatment* or therap*)	394
40	Family Systems Nursing	64
41	Expert patient program*	27
42	25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41	106450
43	24 and 42	2598

Notes: a) Run date: May 22 2018

PRISMA-P Checklist

		Reporting Item	Page Number
10	Identification	#1a Identify the report as a protocol of a systematic review	1
12	Update	#1b If the protocol is for an update of a previous systematic review, identify as such	NA
16		#2 If registered, provide the name of the registry (such as PROSPERO) and registration number	2
20	Contact	#3a Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
25	Contribution	#3b Describe contributions of protocol authors and identify the guarantor of the review	9
29		#4 If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	NA
36	Sources	#5a Indicate sources of financial or other support for the review	10
38	Sponsor	#5b Provide name for the review funder and / or sponsor	10
41	Role of sponsor or funder	#5c Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	10
44	Rationale	#6 Describe the rationale for the review in the context of what is already known	3
48	Objectives	#7 Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	4
54	Eligibility criteria	#8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	6

1	Information	#9	Describe all intended information sources (such as electronic	5
2	sources		databases, contact with study authors, trial registers or other	
3			grey literature sources) with planned dates of coverage	
4				
5				
6	Search strategy	#10	Present draft of search strategy to be used for at least one	16
7			electronic database, including planned limits, such that it	
8			could be repeated	
9				
10				
11	Study records -	#11a	Describe the mechanism(s) that will be used to manage	4
12	data management		records and data throughout the review	
13				
14				
15	Study records -	#11b	State the process that will be used for selecting studies (such	6
16	selection process		as two independent reviewers) through each phase of the	
17			review (that is, screening, eligibility and inclusion in meta-	
18			analysis)	
19				
20				
21				
22	Study records -	#11c	Describe planned method of extracting data from reports	7
23	data collection		(such as piloting forms, done independently, in duplicate), any	
24	process		processes for obtaining and confirming data from investigators	
25				
26				
27	Data items	#12	List and define all variables for which data will be sought	7
28			(such as PICO items, funding sources), any pre-planned data	
29			assumptions and simplifications	
30				
31				
32				
33	Outcomes and	#13	List and define all outcomes for which data will be sought,	7
34	prioritization		including prioritization of main and additional outcomes, with	
35			rationale	
36				
37				
38	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of	See note
39	individual studies		individual studies, including whether this will be done at the	1
40			outcome or study level, or both; state how this information will	
41			be used in data synthesis	
42				
43				
44				
45	Data synthesis	#15a	Describe criteria under which study data will be quantitatively	8
46			synthesised	
47				
48				
49		#15b	If data are appropriate for quantitative synthesis, describe	8
50			planned summary measures, methods of handling data and	
51			methods of combining data from studies, including any	
52			planned exploration of consistency (such as I ² , Kendall's τ)	
53				
54				
55				
56		#15c	Describe any proposed additional analyses (such as	8
57			sensitivity or subgroup analyses, meta-regression)	
58				
59				
60				

1		#15d	If quantitative synthesis is not appropriate, describe the type	8
2			of summary planned	
3				
4				
5	Meta-bias(es)	#16	Specify any planned assessment of meta-bias(es) (such as	See note
6			publication bias across studies, selective reporting within	2
7			studies)	
8				
9				
10	Confidence in	#17	Describe how the strength of the body of evidence will be	See note
11	cumulative		assessed (such as GRADE)	3
12	evidence			
13				
14				
15				

Author notes

1. NA for scoping review
2. NA for scoping reviews
3. NA for scoping reviews

The PRISMA-P checklist is distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. This checklist was completed on 02. June 2018 using <http://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

BMJ Open

Patient-Centered Care for Addictions Treatment: A Scoping Review Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024588.R1
Article Type:	Protocol
Date Submitted by the Author:	03-Oct-2018
Complete List of Authors:	Marchand, Kirsten; University of British Columbia, School of Population and Public Health; Centre for Health Evaluation and Outcome Sciences, Beaumont, Scott; University of British Columbia, School of Population and Public Health; Centre for Health Evaluation and Outcome Sciences, Westfall, Jordan; Canadian Association for People Who Use Drugs MacDonald, Scott; Providence Health Care, Crosstown Clinic Harrison, Scott; Providence Health Care, Crosstown Clinic Marsh, David; Northern Ontario School of Medicine, Schechter, Martin; University of British Columbia, SPPH; Centre for Health Evaluation and Outcome Sciences, Oviedo-Joekes, Eugenia; University of British Columbia, School of Population and Public Health; Centre for Health Evaluation and Outcome Sciences,
Primary Subject Heading:	Addiction
Secondary Subject Heading:	Patient-centred medicine, Public health
Keywords:	Patient-centered care, Client-centered care, Substance-related disorders, Problematic substance use, Addiction treatment, person-centered care

SCHOLARONE™
Manuscripts

Patient-Centered Care for Addictions Treatment: A Scoping Review Protocol

Authors:

Kirsten Marchand^{1, 2}

Scott Beaumont¹

Jordan Westfall³

Scott MacDonald⁴

Scott Harrison⁴

David C. Marsh⁵

Martin T. Schechter^{1, 2}

Eugenia Oviedo-Joekes^{1, 2}

Author affiliation and addresses:

1. School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC, V6T 1Z3, Canada.
2. Centre for Health Evaluation & Outcome Sciences, Providence Health Care, St. Paul's Hospital, 575- 1081 Burrard St., Vancouver, BC, V6Z 1Y6, Canada.
3. Canadian Association for People Who Use Drugs, 46 East Hastings St., Vancouver, BC V6A 1N1, Canada.
4. Providence Health Care, Providence Crosstown Clinic, 84 West Hastings St., Vancouver, BC V6B 1G6, Canada.
5. Northern Ontario School of Medicine, 935 Ramsey Lake Road, Sudbury, ON P3E 2C6, Canada.

Corresponding Author:

Kirsten Marchand

575-1081 Burrard St., Vancouver, BC, V6Z 1Y6, Canada.

kmarchand@cheos.ubc.ca

778-847-8715

Word count (excluding title page, abstract, references, figures and tables): 3,215

Keywords: Patient-centered care; client-centered care; person-centered care; addiction treatment; substance-related disorders; problematic substance use

ABSTRACT:

Introduction: Substance use disorders are chronic conditions that require a multidimensional treatment approach. Despite ongoing efforts to diversify such treatments, evidence continues to illuminate modest rates of treatment engagement and perceived barriers to treatment. Patient-centered care (PCC) is one approach that may strengthen the responsiveness of treatments for people with problematic substance use. The aim of this scoping review is to explore how the principles of patient-centered care have been implemented and operationalized in health care settings for people with problematic substance use.

Methods and analysis: This scoping review follows the iterative stages of the Arksey and O'Malley framework. Both empirical (from Medline, Embase, PsycINFO, CINAHL and ISI Web of Science) and grey literature references will be considered if they focused on populations with problematic substance use and described or measured PCC or one of its principles in a health-oriented context. Two reviewers will independently screen references in two successive stages of title/abstract screening and then full-text screening for references meeting title/abstract criteria. A descriptive overview, tabular and/or graphical summaries, and a directed content analysis will be carried out on extracted data. This scoping review has been registered with Open Science Framework (<https://osf.io/5swvd/>).

Ethics and dissemination: This review will examine the nature and extent to which the principles of PCC have been implemented, defined, and measured. Such evidence will contribute to the operationalization of PCC for people with problematic substance use. A multidisciplinary team has been gathered to represent the needs of people with problematic substance use, health care providers, and decision makers. The team's knowledge users will be engaged throughout this review and will participate in dissemination activities (e.g., workshops, presentations, publications, reports).

ARTICLE SUMMARY: (Strengths and Limitations of this Study)

- This is the first scoping review to systematically explore which principles of patient-centered care have been implemented and their operationalization among people with problematic substance use.
- A multidisciplinary team composed of drug policy advocates, health care providers, decision makers, and academics will lead this scoping review.
- Both the population (people with problematic substance use) and concept of interest (patient-centered care) have been indexed using a variety of terms, which poses a challenge to ensuring breadth of the search.
- A comprehensive search strategy has been developed in consultation with a health sciences librarian to promote a sensitive scope of empirical and grey literature sources.

- This iterative scoping review study has been registered with Open Science Framework to enhance its transparency (<https://osf.io/5swvd/>).

1. INTRODUCTION

Alcohol, tobacco, and illicit substance use continues to be a significant public health concern that accounts for 11.2% of the global burden of disease and 21.1% of all deaths.[1] People with substance use disorders are at an increased risk of mortality and morbidity;[2 3] and some may be further affected by lost family and social support, criminal justice involvement, and social marginalization.[4] However, not all people with problematic substance use follow the same trajectory. Instead, there are individual variations in the personal meaning of substance use, in the intensity and frequency of use, and its associated harms.[4-6] This heterogeneity in substance use disorders contributes to the complexity of its treatment.

It is increasingly accepted that there is no ‘one size fits all’ treatment approach for problematic substance use and that a range of treatments are required to meet the diverse needs and preferences of this population.[5 6] For example, effective pharmacological therapies are available to assist with the treatment of some, but not all, substance use disorders (e.g., tobacco, alcohol, opioid dependence).[7] Treatment may also include psychosocial interventions (e.g., cognitive behavioural therapy, contingency management, or strengths-based treatment) either in combination with pharmacological therapies or alone.[8 9] Regardless of the treatment provided, the main goal is to engage clients in care, since treatment engagement is widely recognized as one of the most important predictors of substance use outcomes.[10 11]

As such, tremendous efforts have been made towards improving client engagement. Examples include: diversified treatment settings that offer traditional residential and hospital-based programs, specialized outpatient programs, and more recently, integrated service models.[7 12] To increase the rate of detection and treatment engagement, opportunities for screening and brief intervention have also been incorporated and expanded outside of specialized substance use treatment programs.[13] Various problem-to-services matching designs have also been developed to increase successful treatment engagement by strengthening alignment between client’s needs and services offered.[14-17]

In spite of these important developments, research continues to demonstrate quite mixed uptake of these practices,[17] as well as varying rates of treatment engagement. [7 12] Globally, it is estimated that 1 out of every 6 people in need of substance use treatment is able to receive it; and this does not imply receipt of evidence- or human-rights based treatments.[18] Even when examining evidence-based treatments, such as opioid agonist treatment, recent systematic reviews suggest a wide range in the rate of treatment retention (e.g., from 37%–91% at 12-month follow-up).[19] There is also a substantial body of qualitative research that has revealed several areas in which clients (and in some cases providers) have perceived challenges with engaging in treatment. A few examples include perceived provider misunderstanding of treatment goals,[20] discrepancies between client and provider’s treatment goals,[21] a lack of treatment

1
2
3 responsiveness to client's perceived needs,[22 23] challenges with involving clients in treatment
4 planning and delivery,[24] and perceived power imbalances, stigma and discrimination.[25-27]
5 This evidence suggests that there remains a need to explore *how* treatment processes can be
6 designed to increase client engagement better respond to client's unique needs, while also
7 considering the diversity of treatments and settings required.
8
9

10 Patient-centered care (PCC) is one potential approach warranting further exploration. PCC is
11 rooted in a philosophy that '*puts the person first*', endeavoring to meet their unique needs and
12 preferences, enhancing their experiences with care, and involving them in all elements of
13 treatment planning and delivery.[28] Some of its origins can be traced back to Carl Rogers'
14 client-centered therapy, which emphasized unconditional positive regard, empathy, and
15 genuineness in the therapeutic process.[29] Over the last two decades, as the concept of PCC has
16 garnered increased attention across the health and social sciences[30 31], its operationalization
17 has included a refinement and expansion of the role of the therapeutic relationship. For example,
18 in nursing, empirically based conceptual frameworks[32-34] agree that PCC entails an approach
19 to care that is holistic, individualized, respectful, and empowering. In medicine, the proposed
20 frameworks converge around similar, but slightly reframed dimensions. Here, emphasis is on a
21 biopsychosocial perspective, seeing the 'patient-as-person', enhancing the therapeutic alliance,
22 and sharing power and responsibility.[35-40] These differences across disciplines (in the
23 conceptual meaning of PCC) have resulted in varying operationalizations.
24
25
26
27
28

29 That the meaning of PCC is currently somewhat context-specific poses challenges to determining
30 the relationship between PCC and treatment process and outcome indicators. For example, a
31 recent meta-analysis showed mixed effects of PCC (defined as shared control or decisions and/or
32 consultations focused on whole person) on improved quality of care, treatment satisfaction and
33 health outcomes.[41] It also found support for generally positive effects of PCC on consultation
34 process measures (e.g., communication about treatments; levels of empathy),[41] suggesting that
35 these approaches might overcome some of the challenges clients have historically experienced
36 engaging in substance use treatment.
37
38
39

40 It is important to recognize that elements of PCC have been recommended or defined as part of
41 some addiction treatment approaches.[6] For example, principles of respect, empathy, or
42 empowerment are integral to some treatments (e.g., motivational interviewing, strengths-based
43 treatment). However, to our knowledge, it is not known to what extent each of the dimensions of
44 PCC have been purposefully implemented or tested across the spectrum of treatment approaches
45 for people with problematic substance use. Bringing this evidence together in a systematic
46 scoping review has the potential to identify cross-setting, discipline and population dimensions
47 of PCC that have been defined, implemented and empirically explored.
48
49
50

51 **2. OBJECTIVE**

52
53 The present scoping review will systematically explore how the principles of patient-centered
54 care have been implemented and operationalized in health care settings for people with
55
56
57
58

1
2
3 problematic substance use. Specifically, this review aims to examine the extent and nature of
4 existing evidence of PCC in addiction research and clinical practice.
5

6 7 **3. METHODS AND ANALYSIS**

8 This scoping review methodology will apply the classic framework developed by Arksey and
9 O'Malley,[42][36] and recent enhancements[43-45] including best practices for conducting and
10 reporting systematic reviews (i.e., Preferred Reporting Items for Systematic Review and Meta-
11 Analysis for Protocols and Scoping Reviews (PRISMA-P and PRISMA-ScR; Supplement 1).[46
12 47] Accordingly, a reflexive and iterative approach will be maintained; particularly during the
13 study screening and data extraction phases, which may become more refined throughout the
14 review. The protocol has been registered through Open Science Framework
15 (<https://osf.io/5swvd/>).[48] DistillerSR software for systematic reviews[49] will be used by both
16 reviewers for screening, extraction, monitoring, and to support synthesis and summarizing of
17 findings.
18
19
20
21

22 **3.1. Stage 1: Defining the Research Question**

23 The research question was developed as a broad framing of the population (i.e., people with
24 problematic substance use), the concept (i.e., patient-centered care) and the context (i.e., health-
25 oriented settings) to be explored. Thus, this scoping review asks:
26
27

- 28 1. Which patient-centered care principles have been implemented in health-oriented
29 settings for people with problematic substance use?
30
- 31 2. How have these patient-centered care principles been operationalized when used in
32 health-oriented settings for people with problematic substance use?
33
- 34 3. What outcomes from the implementation of patient-centered care principles have been
35 empirically measured or tested?
36

37 **3.2. Stage 2: Identifying Relevant Literature**

38 Our goal in developing this search strategy (Supplement 2) is to undertake a comprehensive
39 review of the existing evidence base. However, this particular research question poses a
40 challenge to keyword selection due to the evolution of terms used to describe both the population
41 and concept of interest. For instance, problematic substance use has grown from the pejorative
42 language of the 'addict' to a health-oriented view of 'substance dependent populations' and now
43 onto the more person-focused discourse of 'people with problematic substance use'.[50 51]
44
45
46
47

48 Likewise, as described above, conceptual frameworks of PCC have varied, adding to the
49 complexity of this search. To overcome this challenge, we have developed a search strategy
50 informed by the principles of PCC that have been most consistently (in the previously mentioned
51 frameworks) identified and operationalized, as well as keywords and MeSH terms from
52 systematic reviews[52 53] and empirical references[54-56] previously conducted among our
53 population of interest: (1) *understanding the whole person* to account for the biological,
54 psychological and social aspects of patients' illnesses; (2) *exploring the disease and illness*
55
56
57
58

1
2
3 *experience* to understand the personal meaning of illness and treatment for the patient; (3)
4 *finding common ground* where power, knowledge and responsibility are shared between the
5 patient and provider; and (4) *enhancing the patient-provider relationship* to improve the positive
6 outcomes of treatments provided. We have also engaged in an extensive consultation process
7 with an experienced Health Science Librarian (at the University of British Columbia) as well as
8 the knowledge users represented in our team (authors SM and SH). The search strategy will also
9 be peer reviewed (i.e., PRESS) to promote its rigor and feasibility.[57]

10
11
12
13 Given our interest in undertaking a comprehensive review of existing research and clinical
14 guidelines related to PCC in the addictions field, both empirical (primary studies, previous
15 reviews) and grey literature documents (conference abstracts, reports, and clinical guidelines)
16 will be included in our search. The search for empirical sources will be conducted in the most
17 important electronic databases for the medical and social sciences: Medline (Ovid), Embase
18 (Ovid), PsycINFO, CINAHL, and ISI Web of Science. The search strategy has been developed
19 in Medline (Ovid) and will be adapted to the other databases. The search strategy will include
20 subject headings, related terms, and keywords as necessary for the research question. Boolean
21 logic and operators (i.e., ‘and’, ‘or’, ‘not’) will be used to combine and refine search terms and
22 concepts.
23

24
25
26 For the grey literature search strategy, we will utilize recommended resources[58] and consult
27 with the Health Sciences Librarian and our team’s knowledge users to devise a database specific
28 approach. The search for abstracts, reports, and clinical guidelines will be carried out in several
29 Canadian-specific databases: British Columbia Guidelines and Protocols Databases, CPG
30 Infobase, the Registered Nurses’ Association Clinical Practice Guidelines Program, and Des
31 Libris. For international grey literature documents, we will search National Guideline
32 Clearinghouse, TRIP, Google, and Google Scholar databases.
33

36 37 **3.3. Stage 3: Study Selection**

38 A two-stage collaborative review process will be used to select references. Eligibility criteria
39 have been developed *a priori*, in consultation with the study team. The screening form will be
40 piloted on the first 20 citations of the initial Medline (Ovid) search to test both the criteria and
41 reviewer agreement. Two independent reviewers (authors KM and SB) will apply eligibility
42 criteria during the initial title/abstract review. After each review stage, the reviewer’s agreement
43 will be assessed and a third reviewer (author EOJ) will be consulted in cases of disagreement,
44 until consensus is achieved.
45

46
47
48 A title/abstract (or executive summary for reports and guidelines) will be eligible for full text
49 screening if it:
50

51 a) Refers to people with problematic substance use (including tobacco, alcohol, cannabis,
52 stimulant, opioid use, or dual diagnoses);
53
54
55
56
57
58

b) Is about delivering patient-centered care or one of its principles (including care that understands the whole person; explores the disease and illness experience; finds common ground and enhances the patient-provider relationship);

c) Is set in a health-oriented context (including inpatient or outpatient hospital settings, emergency departments, community-based or primary care health settings, and any specialized drug treatment or low-threshold agencies and programs; excluding prison-based health programs and self-help models such as narcotics or alcoholics anonymous); and

d) Was published between January 1, 1960 and July 1, 2018 in English, French, Spanish, Italian, Portuguese or German.

Full text empirical articles, reports and guidelines will then be obtained for titles/abstracts meeting these above criteria and will undergo further screening. In addition to the title/abstract criteria, full texts will be included if:

e) It provided an operational definition of the patient-centered care framework that was delivered to people with problematic substance use in the health-oriented context; and

f) It observed at least one outcome (e.g., treatment compliance, treatment satisfaction) of the patient-centered treatment approach (this criterion pertains to empirical articles only).

As such, articles that provide only a recommendation to adopt PCC or an opinion of how PCC should be implemented in health-oriented settings for people with problematic substance use will not be included.

3.4. Stage 4: Data Extraction

Results of the search will be collated in DistillerSR,[49] allowing the research team to de-duplicate and perform data extraction. We will follow recommended data charting methods[42 47] to systematically capture relevant details for studies/reports and guidelines (Table 1). Data charting forms will be piloted with the first 5 empirical and grey literature references and may be adapted thereafter (with input from the teams' knowledge users).

Table 1. Data extraction and charting for empirical and grey literature sources

Domain/Subdomain	Description
1. General Document Details	
1.1 Reference Type	Empirical study, case study, review, commentary, report, guideline
1.2 Publication Year	Year of publication
1.3 Country and Location	Country of publication (and location if provided)
1.4 Publication Language	Language of publication
2. Empirical Study References (if applicable)	
2.1 Research objective	What was the research objective or specific question to be tested (if relevant)

2.2 Study design	Was the study design observational, experimental, or qualitative?
2.3 Study population	What were the eligibility criteria? Would the population be classified as primarily: tobacco, cannabis, alcohol, opioid, stimulant, or comorbid substance use and mental illness?
2.4 Patient-centered care intervention	What was the operational definition of patient-centered care used (including the definition of specific principles, if available)? How long was the intervention provided or observed for?
2.5 Context/setting	What health-oriented context was the PCC intervention apart of? What health professionals were involved?
2.6 Study outcomes	For quantitative studies, what were the primary and secondary outcomes measured? For qualitative studies, what outcomes were described?
2.7 Important results	What were the main results of the study? Were there any important sub-group (e.g., by sex and gender, by primary substance, by health care provider) analyses?
2.8 Limitations	What limitations did the authors describe? What others might there be?
3. Grey Literature References (if applicable)	
3.1 Target audience	Is there a target audience specified for the guideline/report (e.g., policy/decision maker, health care provider, patient/client/family)?
3.2 Reference population	If available, how was the target patient population defined? Any specific eligibility criteria used? Would the population be classified as primarily: tobacco, cannabis, alcohol, opioid, stimulant, or comorbid substance use and mental illness?
3.3 Patient-centered care operational definition	What was the operational definition of patient-centered care used (including the definition of specific principles, if available)?
3.4 Context/setting	What health-oriented context was the PCC intervention apart of? What health professionals were involved?
3.5 Intervention and outcomes	If applicable, was a specific patient-centered intervention described (e.g., a training module, a clinical approach)? Were any outcomes of PCC reported (e.g., patient or provider satisfaction)?
3.6 Program evaluation	If available, what results were reported from any ongoing program evaluations?

3.5. Stage 5: Collating, Summarizing and Reporting the Results

We will present a descriptive overview (including tabular and/or graphical summaries) of the eligible full texts.[42] We will also summarize studies by each broader category of substances primarily used (i.e., tobacco, cannabis, alcohol, opioid, stimulant, dual diagnosis). Displaying information in this way will highlight population-specific similarities and differences in PCC, its

1
2
3 definition and outcomes. This will facilitate the identification of future directions for research
4 and practice. All tables and charts will include narrative summaries, relating the findings to the
5 review's research question. Additionally, we will develop a final report of the review[47]
6 according to PRISMA-ScR guidelines.[46]
7
8

9 Given that one aim of this review is to understand *how* PCC has been defined and implemented
10 in health care services for people with problematic substance use, a directed content analysis will
11 be carried out on included guidelines. This approach has been deemed most suitable to the
12 present review, since it allows existing theory (in our case, principles of PCC defined a priori to
13 guide the coding and analysis), while still allowing new evidence to emerge.[59] Specifically, we
14 are interested in qualitatively analyzing the definition of PCC adopted in the guidelines, how it
15 was developed, which health care providers were involved, and any outcomes or ongoing
16 evaluations of the program. To do so, data from the guidelines will be imported to MAXQDA,
17 version 12,[60] a qualitative analysis software program that supports a multi-user approach. This
18 analysis will be conducted by authors KM, SB, and EOJ, who have prior experience conducting
19 thematic analysis on similar topics.[61 62] As is common in directed content qualitative
20 analysis,[59] a coding framework will be developed a priori, and will then be applied by authors
21 KM and SB independently. Results from this analysis will be summarized and—where
22 relevant—numerical summaries may also be used to provide additional context to the themes
23 (e.g., number of clients treated, number of staff).
24
25
26
27
28

29 **3.6. Stage 6: Consultation Process and Engagement of Knowledge Users**

30
31 The ultimate aim of this review is to generate evidence that can be used to inform decision-
32 makers and health care providers on the feasibility, implications, and potential outcomes
33 associated with PCC for substance use treatment. To achieve this goal, we have engaged a multi-
34 disciplinary team of knowledge users who represent the needs of: people with problematic
35 substance use, health care providers, and decision makers. Consulting with the teams' health care
36 providers and decision-makers (authors SH, SM, and DCM) will promote a methodology that
37 reflects the realities of patient-provider roles and the health care system's organization. Also, our
38 team's drug policy knowledge user (author JW) represents a national organization of people who
39 use drugs and this critical perspective will ensure that all aspects of this review are rooted in the
40 client-centered needs of this diverse population. The specific contributions of the Knowledge
41 Users to each stage of this review have been defined throughout. At this time, Knowledge Users
42 have reviewed early drafts of the search strategy, identifying additional terms that are important
43 for inclusion given the population, concept, and contexts of interest (e.g., trauma-informed care
44 and culturally-safe care). Knowledge Users have also provided several grey-literature references
45 (clinical guidelines and reports) to be considered for inclusion. As the project continues to
46 evolve, all Knowledge Users will be involved in supporting the interpretation of findings and
47 their dissemination.
48
49
50
51
52
53

54 **4. ETHICS AND DISSEMINATION**

1
2
3 As substance use disorders are increasingly recognized as a chronic conditions often marked by
4 cycles of relapse and recovery, the public health care system is considering how existing
5 treatment and intervention approaches can be optimized to meet the long-term and evolving
6 goals of clients.[18] Adopting patient- or person-centered approaches may increase the
7 responsiveness of existing treatments to individual client needs, expectations, and preferences.
8 To our knowledge, this review will be the first to systematically examine the extent and nature of
9 existing evidence of PCC in addiction research and clinical practice.
10
11
12

13 Our dissemination strategy will utilize traditional approaches, including open-access peer-
14 reviewed publication(s), scientific presentations, and a report. Additionally, we are committed to
15 promoting further action based on the potential findings of this review. Therefore, we will host a
16 half-day roundtable meeting—bringing together people with problematic substance use, health
17 care providers (from diverse settings), and decision-makers to brainstorm potential opportunities
18 for future areas of research and clinical practice work. For example, we may engage in a concept
19 mapping exercise, using the findings of this review to integrate stakeholders' knowledge,
20 interpretations, and priorities into practice. The multidisciplinary nature of this team will
21 facilitate and support our goal of bringing together these different representatives together.
22
23
24

25 **5. PATIENT AND PUBLIC INVOLVEMENT**

26
27 This scoping review protocol has engaged the expertise of a national organization of people who
28 use(d) drugs through the involvement of this organizations' President. This knowledge user
29 (author JW) has made contributions to the development of the research question and will also be
30 extensively involved during the interpretation and dissemination phases of this project.
31
32
33
34

35 **AUTHOR CONTRIBUTIONS:**

36 KM (review guarantor) led the design and conceptualisation of this review and drafted the
37 protocol with primary support from SB, MTS, and EOJ. SB, SH, and EOJ were involved in
38 refining the search strategy, including key words. SM, SH, DCM, and JW were involved in
39 establishing eligibility criteria and data extraction forms. All authors provided feedback on the
40 manuscript and approval to the publishing of this protocol manuscript.
41
42
43
44

45 **AMENDMENTS:** Not applicable
46

47 **SUPPORT (SOURCES, SPONSOR, ROLE OF SPONSOR OR FUNDER):** Funding for this
48 scoping review has been provided by the Canadian Institutes of Health Research (Operating
49 Grant: Opioid Crisis Knowledge Synthesis). We would also like to acknowledge Ursula Ellis,
50 Health Sciences Librarian (University of British Columbia), who has provided invaluable
51 expertise to the development and refinement of the search strategy of this scoping review.
52
53
54

55 **COMPETING INTERESTS:** The authors have no competing interests to declare.
56
57
58

References

1. Gakidou E, Afshin A, Abajobir AA, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. *The Lancet* 2017;390(10100):1345-422. doi: 10.1016/S0140-6736(17)32366-8
2. Holford TR, Meza R, Warner KE, et al. Tobacco control and the reduction in smoking-related premature deaths in the united states, 1964-2012. *JAMA* 2014;311(2):164-71. doi: 10.1001/jama.2013.285112
3. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. *Lancet* 2013;382(9904):1575-86. doi: 10.1016/s0140-6736(13)61611-6 [published Online First: 2013/09/03]
4. Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. *Lancet* 2010;376(9752):1558-65. doi: [http://dx.doi.org/10.1016/S0140-6736\(10\)61462-6](http://dx.doi.org/10.1016/S0140-6736(10)61462-6)
5. Hammer G. Trust and relationship as cornerstones of successful psychotherapy. In: Tatarsky A, Tatarsky A, eds. *Harm reduction psychotherapy: A new treatment for drug and alcohol problems*. Lanham, MD, US: Jason Aronson 2002:106-35.
6. Abou-Saleh MT, Tarter RE, Salloum IM. Substance use disorders. In: Mezzich JE, Botbol M, Christodoulou GN, et al., eds. *Person centered psychiatry*. Cham, Switzerland: Springer International Publishing 2016:325-43.
7. Substance Abuse and Mental Health Services Administration. Chapter 4, Early Intervention, Treatment, And Management of Substance Use Disorders. In: Office of the Surgeon General (US), ed. *Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health*. Washington (DC), 2016.
8. Jhanjee S. Evidence Based Psychosocial Interventions in Substance Use. *Indian Journal of Psychological Medicine* 2014;36(2):112-18. doi: 10.4103/0253-7176.130960
9. Magill M, Ray LA. Cognitive-Behavioral Treatment With Adult Alcohol and Illicit Drug Users: A Meta-Analysis of Randomized Controlled Trials. *Journal of Studies on Alcohol and Drugs* 2009;70(4):516-27. doi: 10.15288/jsad.2009.70.516
10. Hubbard RL, Craddock SG, Flynn PM, et al. Overview of One-Year Follow-Up Outcomes in the Drug Abuse Treatment Outcome Study (DATOS). *Psychology of Addictive Behaviors* 1997;11(4 special issue):261-78.
11. Simpson DD, Joe GW, Rowan-Szal GA. Drug abuse treatment retention and process effects on follow-up outcomes. *Drug Alcohol Depend* 1997;47(3):227-35.
12. Substance Abuse and Mental Health Services Administration. Chapter 6, Health Care Systems and Substance Use Disorders. In: US Department of Health and Human Services,

- 1
2
3 ed. Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and
4 Health Washington (DC)2016.
5
6 13. Babor TF, McRee BG, Kassebaum PA, et al. Screening, Brief Intervention, and Referral to
7 Treatment (SBIRT). *Substance Abuse* 2007;28(3):7-30. doi: 10.1300/J465v28n03_03
8
9 14. Marsh JC, Cao D, Shin HC. Closing the Need-Service Gap: Gender Differences in Matching
10 Services to Client Needs in Comprehensive Substance Abuse Treatment. *Social work*
11 *research* 2009;33(3):183-92. [published Online First: 2009/09/01]
12
13 15. Hser YI, Polinsky ML, Maglione M, et al. Matching clients' needs with drug treatment
14 services. *J Subst Abuse Treat* 1999;16(4):299-305. [published Online First: 1999/06/01]
15
16 16. Group PMR. Matching patients with alcohol disorders to treatments: Clinical
17 implications from Project MATCH. *Journal of Mental Health* 1998;7(6):589-602. doi:
18 10.1080/09638239817743
19
20 17. Alexander JA, Nahra TA, Lemak CH, et al. Tailored treatment in the outpatient substance
21 abuse treatment sector: 1995-2005. *Journal of Substance Abuse Treatment* 2008;34(3):282-
22 92.
23
24 18. United Nations Office on Drugs and Crime. International Standards for the Treatment of
25 Drug Use Disorders. Geneva: World Health Organization, 2017.
26
27 19. Timko C, Schultz NR, Cucciare MA, et al. Retention in medication-assisted treatment for
28 opiate dependence: A systematic review. *J Addict Dis* 2016;35(1):22-35. doi:
29 10.1080/10550887.2016.1100960 [published Online First: 2015/10/16]
30
31 20. Rance J, Treloar C. "We are people too": consumer participation and the potential
32 transformation of therapeutic relations within drug treatment. *International Journal of*
33 *Drug Policy* 2015;26(1):30-36. doi: 10.1016/j.drugpo.2014.05.002
34
35 21. Joosten EAG, De Weert-Van Oene GH, Sensky T, et al. Treatment goals in addiction
36 healthcare: The perspectives of patients and clinicians. *International Journal of Social*
37 *Psychiatry* 2011;57(3):263-76. doi: 10.1177/0020764009354835
38
39 22. McNeil R, Kerr T, Pauly B, et al. Advancing patient-centered care for structurally
40 vulnerable drug-using populations: A qualitative study of the perspectives of people who
41 use drugs regarding the potential integration of harm reduction interventions into
42 hospitals. *Addiction* 2016;111(4):685-94. doi: 10.1111/add.13214
43
44 23. Pauly B, McCall J, Browne AJ, et al. Toward cultural safety: Nurse and patient
45 perceptions of illicit substance use in a hospitalized setting. *Advances in Nursing Science*
46 2015;38(2):121-35. doi: 10.1097/ANS.0000000000000070
47
48 24. Bryant J, Bryant J, Saxton M, et al. Consumers' and providers' perspectives about
49 consumer participation in drug treatment services: is there support to do more? What are
50 the obstacles? *Drug and Alcohol Review* 2008;27(2):138-44. doi:
51 10.1080/09595230701829405
52
53 25. Fischer J, Neale J. Involving drug users in treatment decisions: An exploration of
54 potential problems. *Drugs: Education, Prevention & Policy* 2008;15(2):161-75. doi:
55 10.1080/09687630701391604
56
57
58

26. Strike C, Rufo C. Embarrassing, degrading, or beneficial: patient and staff perspectives on urine drug testing in methadone maintenance treatment. *Journal of Substance Use* 2010;15(5):303-12. doi: 10.3109/14659890903431603
27. Palis H, Marchand K, Peng D, et al. Factors Associated with Perceived Abuse in the Health Care System Among Long-Term Opioid Users: A Cross-Sectional Study. *Subst Use Misuse* 2016;51(6):763-76. doi: 10.3109/10826084.2016.1155605 [published Online First: 2016/04/21]
28. Berwick DM. What 'patient-centered' should mean: confessions of an extremist. *Health Aff (Millwood)* 2009;28(4):w555-65. doi: 10.1377/hlthaff.28.4.w555 [published Online First: 2009/05/21]
29. Rogers C. *On Becoming a Person. A Therapist's View of Psychotherapy*. Boston: Houghton Mifflin Company 1961.
30. Institute of Medicine (IOM). *Crossing the Quality Chasm: A New Health System for the 21st Century*. 2001.
31. Beaulieu MD. President's message: toward a patient-centred health care system. *Can Fam Physician* 2013;59(1):109,10. [published Online First: 2013/01/24]
32. Slater L. Person-centredness: a concept analysis. *Contemp Nurse* 2006;23(1):135-44. doi: 10.5555/conu.2006.23.1.135 [published Online First: 2006/11/07]
33. Hobbs JL. A dimensional analysis of patient-centered care. *Nurs Res* 2009;58(1):52-62. doi: 10.1097/NNR.0b013e31818c3e79 [published Online First: 2008/12/19]
34. Morgan S, Yoder LH. A concept analysis of person-centered care. *J Holist Nurs* 2012;30(1):6-15. doi: 10.1177/0898010111412189 [published Online First: 2011/07/21]
35. Mead N, Bower P. Patient-centredness: a conceptual framework and review of the empirical literature. *Soc Sci Med* 2000;51(7):1087-110. [published Online First: 2000/09/27]
36. Stewart M. Towards a global definition of patient centred care. *BMJ* 2001;322(7284):444-5. [published Online First: 2001/02/27]
37. Robinson JH, Callister LC, Berry JA, et al. Patient-centered care and adherence: definitions and applications to improve outcomes. *J Am Acad Nurse Pract* 2008;20(12):600-7. doi: 10.1111/j.1745-7599.2008.00360.x [published Online First: 2009/01/06]
38. McMillan SS, Kendall E, Sav A, et al. Patient-centered approaches to health care: a systematic review of randomized controlled trials. *Medical care research and review : MCRR* 2013;70(6):567-96. doi: 10.1177/1077558713496318 [published Online First: 2013/07/31]
39. Scholl I, Zill JM, Harter M, et al. An integrative model of patient-centeredness - a systematic review and concept analysis. *PLoS One* 2014;9(9):e107828. doi: 10.1371/journal.pone.0107828 [published Online First: 2014/09/18]
40. Santana MJ, Manalili K, Jolley RJ, et al. How to practice person-centred care: A conceptual framework. *Health Expectations : An International Journal of Public Participation in Health Care and Health Policy* 2018;21(2):429-40. doi: 10.1111/hex.12640

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
41. Dwamena F, Holmes-Rovner M, Gaulden CM, et al. Interventions for providers to promote a patient-centred approach in clinical consultations. *Cochrane Database Syst Rev* 2012;12:Cd003267. doi: 10.1002/14651858.CD003267.pub2 [published Online First: 2012/12/14]
 42. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. *International Journal of Social Research Methodology* 2005;8(1):19-32. doi: 10.1080/1364557032000119616
 43. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. *Implementation Science* 2010;5(1):69. doi: 10.1186/1748-5908-5-69
 44. Daudt HM, van Mossel C, Scott SJ. Enhancing the scoping study methodology: a large, inter-professional team's experience with Arksey and O'Malley's framework. *BMC Medical Research Methodology* 2013;13(1):48. doi: 10.1186/1471-2288-13-48
 45. Colquhoun HL, Levac D, O'Brien KK, et al. Scoping reviews: time for clarity in definition, methods, and reporting. *J Clin Epidemiol* 2014;67(12):1291-4. doi: 10.1016/j.jclinepi.2014.03.013 [published Online First: 2014/07/19]
 46. Tricco AC, Lillie E, Zarin W, et al. Prisma extension for scoping reviews (PRISMA-ScR): Checklist and explanation. *Annals of Internal Medicine* 2018 doi: 10.7326/M18-0850
 47. Joanna Briggs Institute. The Joanna Briggs Institute Reviewers' Manual 2015: Methodology for JBI Scoping Reviews. Australia, 2015.
 48. Center for Open Science. Open Science Framework Charlottesville, VA2011 [cited 2018. Available from: <https://osf.io> accessed 07-MAY-2018.
 49. DistillerSR: Systematic Review and Literature Review Software [program]. Ottawa, Canada: Evidence Partners, 2016.
 50. Kelly JF, Saitz R, Wakeman S. Language, Substance Use Disorders, and Policy: The Need to Reach Consensus on an "Addiction-ary". *Alcoholism Treatment Quarterly* 2016;34(1):116-23. doi: 10.1080/07347324.2016.1113103
 51. Broyles LM, Binswanger IA, Jenkins JA, et al. Confronting inadvertent stigma and pejorative language in addiction scholarship: a recognition and response. *Subst Abuse* 2014;35(3):217-21. doi: 10.1080/08897077.2014.930372 [published Online First: 2014/06/10]
 52. Barrio P, Gual A. Patient-centered care interventions for the management of alcohol use disorders: a systematic review of randomized controlled trials. *Patient Prefer Adherence* 2016;10:1823-45. doi: 10.2147/ppa.s109641 [published Online First: 2016/10/04]
 53. Friedrichs A, Spies M, Härter M, et al. Patient preferences and Shared Decision Making in the treatment of substance use disorders: A systematic review of the literature. *PLoS ONE* 2016;11(1)
 54. Schwartz RP, Kelly SM, Mitchell SG, et al. Patient-centered methadone treatment: a randomized clinical trial. *Addiction* 2017;112(3):454-64. doi: 10.1111/add.13622

- 1
2
3 55. Joosten E, de Weert G, Sensky T, et al. Effect of shared decision-making on therapeutic
4 alliance in addiction health care. *Patient Prefer Adherence* 2008;2:277-85. [published
5 Online First: 2008/01/01]
6
- 7 56. Joosten EAG, De Weert-Van Oene GH, Sensky T, et al. Treatment Goals in Addiction
8 Healthcare: the Perspectives of Patients and Clinicians. *International Journal of Social*
9 *Psychiatry* 2010;57(3):263-76. doi: 10.1177/0020764009354835
10
- 11 57. McGowan J, Sampson M, Salzwedel DM, et al. PRESS Peer Review of Electronic Search
12 Strategies: 2015 Guideline Statement. *J Clin Epidemiol* 2016;75:40-6. doi:
13 10.1016/j.jclinepi.2016.01.021 [published Online First: 2016/03/24]
14
- 15 58. Canadian Agency for Drugs and Technologies in Health. Grey Matters: a practical tool
16 for searching health-related grey literature. 2015 [Available from:
17 <https://www.cadth.ca/resources/finding-evidence/grey-matters> accessed November 22,
18 2017.
19
- 20 59. Hsieh H-F, Shannon SE. Three Approaches to Qualitative Content Analysis. *Qualitative*
21 *Health Research* 2005;15(9):1277-88. doi: 10.1177/1049732305276687
22
- 23 60. MAXQDA. Qualitative Analysis Software [program], 2015.
24
- 25 61. Oviedo-Joekes E, Marchand K, Palis H, et al. Predictors of treatment allocation guesses
26 in a randomized controlled trial testing double-blind injectable hydromorphone and
27 diacetylmorphine for severe opioid use disorder. *Addiction Research & Theory*
28 2017;25(4):263-72. doi: 10.1080/16066359.2016.1263729
29
- 30 62. Oviedo-Joekes E, Marchand K, Lock K, et al. A chance to stop and breathe: participants'
31 experiences in the North American Opiate Medication Initiative clinical trial. *Addiction*
32 *science & clinical practice* 2014;9:21-31. doi: 10.1186/1940-0640-9-21 [published Online
33 First: 2014/09/30]
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

PRISMA-P Checklist

		Reporting Item	Page Number
Identification	#1a	Identify the report as a protocol of a systematic review	1
Update	#1b	If the protocol is for an update of a previous systematic review, identify as such	NA
	#2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Contact	#3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contribution	#3b	Describe contributions of protocol authors and identify the guarantor of the review	10
	#4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	NA
Sources	#5a	Indicate sources of financial or other support for the review	10
Sponsor	#5b	Provide name for the review funder and / or sponsor	10
Role of sponsor or funder	#5c	Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	10
Rationale	#6	Describe the rationale for the review in the context of what is already known	3-4
Objectives	#7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	4-5
Eligibility criteria	#8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be	6-7

used as criteria for eligibility for the review

1				
2				
3	Information	#9	Describe all intended information sources (such as	5-6
4	sources		electronic databases, contact with study authors, trial	
5			registers or other grey literature sources) with planned	
6			dates of coverage	
7				
8				
9				
10	Search strategy	#10	Present draft of search strategy to be used for at least one	Supplement
11			electronic database, including planned limits, such that it	2
12			could be repeated	
13				
14				
15	Study records -	#11a	Describe the mechanism(s) that will be used to manage	4
16	data management		records and data throughout the review	
17				
18				
19	Study records -	#11b	State the process that will be used for selecting studies	6
20	selection process		(such as two independent reviewers) through each phase	
21			of the review (that is, screening, eligibility and inclusion in	
22			meta-analysis)	
23				
24				
25				
26	Study records -	#11c	Describe planned method of extracting data from reports	7
27	data collection		(such as piloting forms, done independently, in duplicate),	
28	process		any processes for obtaining and confirming data from	
29			investigators	
30				
31				
32				
33	Data items	#12	List and define all variables for which data will be sought	7-8
34			(such as PICO items, funding sources), any pre-planned	
35			data assumptions and simplifications	
36				
37				
38				
39	Outcomes and	#13	List and define all outcomes for which data will be sought,	7
40	prioritization		including prioritization of main and additional outcomes,	
41			with rationale	
42				
43				
44	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of	See note 1
45	individual studies		individual studies, including whether this will be done at the	
46			outcome or study level, or both; state how this information	
47			will be used in data synthesis	
48				
49				
50				
51	Data synthesis	#15a	Describe criteria under which study data will be	8-9
52			quantitatively synthesised	
53				
54				
55		#15b	If data are appropriate for quantitative synthesis, describe	8-9
56			planned summary measures, methods of handling data and	
57			methods of combining data from studies, including any	
58				
59				
60				

planned exploration of consistency (such as I², Kendall's τ)

#15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) 8-9

#15d If quantitative synthesis is not appropriate, describe the type of summary planned 8-9

Meta-bias(es) #16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) See note 2

Confidence in cumulative evidence #17 Describe how the strength of the body of evidence will be assessed (such as GRADE) See note 3

Author notes

1. NA for scoping review
2. NA for scoping reviews
3. NA for scoping reviews

The PRISMA-P checklist is distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. This checklist was completed on 02. June 2018 using <http://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

Table 1. Medline (Ovid) search strategy

Search term/line number	Conceptual term of interest	Search term entered into Ovid-Medline	Number of hits
1	Substance-Related Disorders	exp Substance-Related Disorders	258462
2	Street Drugs	exp Street Drugs	11263
3	Substance abuser	substance abus*	49532
4	Substance dependent	substance dependen*	2720
5	Substance misuse	substance misus*	2150
6	Problematic substance use	Problematic substance adj2 (use* or usage or using)	254
7	People who inject drugs	(people who inject drug* or PWID)	1740
8	Injection drug use	injection drug "(use or user or usage or using)" or IDU	2794
9	People who use drugs	"people who use drugs" or PWUD	343
10	Illicit substance use	(illicit or street or illegal) adj2 (drug or substance) adj2 (use* or usage or using)	5848
11	opioid dependence	opioid adj2 (addict* or abus* or dependen* or misus* or problem* or disorder*)	15537
12	opiate dependence	opiate adj2 (addict* or abus* or dependen* or misus* or problem* or disorder*)	3475
13	narcotic dependence	narcotic adj2 (addict* or abus* or dependen* or misus* or problem* or disorder*)	1279
14	heroin	heroin	17865
15	stimulant use disorder	"stimulant use disorder"	40

16	exp crack cocaine	exp crack cocaine	1343
17	exp cocaine smoking	exp cocaine smoking	4
18	cocaine dependence	((cocaine or crack) adj2 (addict* or abus* or dependen* or misus* or problem* or disorder*))	11806
19	amphetamine dependence	(amphetamine or crystal methamphetamine or crystal meth) adj1 (addict* or abus* or dependen* or misus* or problem* or disorder*)	592
20	alcohol dependence	alcohol adj2 (addict* or abus* or dependen* or misus* or problem* or disorder*)	50104
21	cannabis dependence	cannabis adj2 (addict* or abus* or dependen* or disorder*)	1917
22	tobacco dependence	(tobacco or nicotine or smok*) adj2 (dependen* or disorder* or cessation)	45598
23	Diagnosis, Dual (Psychiatry)	Diagnosis, Dual (Psychiatry)	3372
24		1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23	337412
25	exp Patient-Centered Care	exp Patient-Centered Care	16653
26	Patient centered care	((patient or client or person) adj1 cent?red adj1 (care or treatment* or therap*))	20713
27	Patient focused care	((patient or client or person) adj1 focus?ed adj1 (care or treatment* or therap*))	425
28	Patient participation in treatment planning, process, decisions	(patient or client) adj1 (autonom* or involve* or control or empower*) adj1 (decision making or care or practic* or treatment* or plan*)	126
29	Collaborative care	collaborative adj1 (care or practic* or treatment* or plan*)	3803
30	Shared decision-making	(shared or joint or collaborative) adj2 decision making	6279
31	Therapeutic alliance	therapeutic alliance	9027
32	Relational practice	relational practic*	44

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

33	Enhanced patient-provider relationship	(physician or doctor or nurse or professional or provider) adj1 (patient or client) adj1 (enhanc* or alliance* or empower* or support*)	304
34	Enhanced patient-provider communication	(physician or doctor or nurse or professional or provider) adj1 (patient or client) adj1 communicat*	4230
35	Holistic Nursing	Holistic Nursing/	3135
36	Trauma informed care	trauma adj1 (cent?red or informed) adj1 (care or approach or treatment* or therap*)	263
37	Culturally safe care	cultural* adj1 (safe or sensitive) adj1 (care or approach or treatment* or therap*)	395
39	Family Systems Nursing	Family Systems Nursing	64
39	Expert patient program	expert patient program*	27
40		25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39	40281
41		24 and 40	896

Update and Run Date: June 27, 2018

BMJ Open

Patient-Centered Care for Addictions Treatment: A Scoping Review Protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024588.R2
Article Type:	Protocol
Date Submitted by the Author:	27-Nov-2018
Complete List of Authors:	Marchand, Kirsten; University of British Columbia, School of Population and Public Health; Centre for Health Evaluation and Outcome Sciences, Beaumont, Scott; University of British Columbia, School of Population and Public Health; Centre for Health Evaluation and Outcome Sciences, Westfall, Jordan; Canadian Association for People Who Use Drugs MacDonald, Scott; Providence Health Care, Crosstown Clinic Harrison, Scott; Providence Health Care, Crosstown Clinic Marsh, David; Northern Ontario School of Medicine, Schechter, Martin; University of British Columbia, SPPH; Centre for Health Evaluation and Outcome Sciences, Oviedo-Joekes, Eugenia; University of British Columbia, School of Population and Public Health; Centre for Health Evaluation and Outcome Sciences,
Primary Subject Heading:	Addiction
Secondary Subject Heading:	Patient-centred medicine, Public health
Keywords:	Patient-centered care, Client-centered care, Substance-related disorders, Problematic substance use, Addiction treatment, person-centered care

SCHOLARONE™
Manuscripts

Patient-Centered Care for Addictions Treatment: A Scoping Review Protocol

Authors:

Kirsten Marchand^{1,2}

Scott Beaumont¹

Jordan Westfall³

Scott MacDonald⁴

Scott Harrison⁴

David C. Marsh⁵

Martin T. Schechter^{1,2}

Eugenia Oviedo-Joekes^{1,2}

Author affiliation and addresses:

1. School of Population and Public Health, University of British Columbia, 2206 East Mall, Vancouver, BC, V6T 1Z3, Canada.
2. Centre for Health Evaluation & Outcome Sciences, Providence Health Care, St. Paul's Hospital, 575- 1081 Burrard St., Vancouver, BC, V6Z 1Y6, Canada.
3. Canadian Association for People Who Use Drugs, 46 East Hastings St., Vancouver, BC V6A 1N1, Canada.
4. Providence Health Care, Providence Crosstown Clinic, 84 West Hastings St., Vancouver, BC V6B 1G6, Canada.
5. Northern Ontario School of Medicine, 935 Ramsey Lake Road, Sudbury, ON P3E 2C6, Canada.

Corresponding Author:

Kirsten Marchand

575-1081 Burrard St., Vancouver, BC, V6Z 1Y6, Canada.

kmarchand@cheos.ubc.ca

778-847-8715

Word count (excluding title page, abstract, references, figures and tables): 3,244

Keywords: Patient-centered care; client-centered care; person-centered care; addiction treatment; substance-related disorders; problematic substance use

ABSTRACT:

Introduction: Substance use disorders are chronic conditions that require a multidimensional treatment approach. Despite ongoing efforts to diversify such treatments, evidence continues to illuminate modest rates of treatment engagement and perceived barriers to treatment. Patient-centered care (PCC) is one approach that may strengthen the responsiveness of treatments for people with problematic substance use. The aim of this scoping review is to explore how the principles of PCC have been implemented and operationalized in health care settings for people with problematic substance use.

Methods and analysis: This scoping review follows the iterative stages of the Arksey and O'Malley framework. Both empirical (from Medline, Embase, PsycINFO, CINAHL and ISI Web of Science) and grey literature references will be considered if they focused on populations with problematic substance use and described or measured PCC or one of its principles in a health-oriented context. Two reviewers will independently screen references in two successive stages of title/abstract screening and then full-text screening for references meeting title/abstract criteria. A descriptive overview, tabular and/or graphical summaries, and a directed content analysis will be carried out on extracted data. This scoping review has been registered with Open Science Framework (<https://osf.io/5swvd/>).

Ethics and dissemination: This review will systematically examine the extent and nature of existing evidence of PCC in addiction research and clinical practice. Such evidence will contribute to the operationalization of PCC for people with problematic substance use. A multidisciplinary team has been gathered to represent the needs of people with problematic substance use, health care providers, and decision makers. The team's knowledge users will be engaged throughout this review and will participate in dissemination activities (e.g., workshops, presentations, publications, reports).

ARTICLE SUMMARY: (Strengths and Limitations of this Study)

- This is the first scoping review to systematically explore which principles of patient-centered care have been implemented and their operationalization among people with problematic substance use.
- A multidisciplinary team composed of drug policy advocates, health care providers, decision makers, and academics will lead this scoping review.
- Both the population (people with problematic substance use) and concept of interest (patient-centered care) have been indexed using a variety of terms, which poses a challenge to ensuring breadth of the search.
- A comprehensive search strategy has been developed in consultation with a health sciences librarian to promote a sensitive scope of empirical and grey literature sources.
- This iterative scoping review study has been registered with Open Science Framework to enhance its transparency (<https://osf.io/5swvd/>).

1. INTRODUCTION

Alcohol, tobacco, and illicit substance use continues to be a significant public health concern that accounts for 11.2% of the global burden of disease and 21.1% of all deaths.[1] People with substance use disorders are at an increased risk of mortality and morbidity;[2 3] and some may be further affected by lost family and social support, criminal justice involvement, and social marginalization.[4] However, not all people with problematic substance use follow the same trajectory. Instead, there are individual

1
2
3
4 variations in the personal meaning of substance use, in the intensity and frequency of
5 use, and its associated harms.[4-6] This heterogeneity in substance use disorders
6 contributes to the complexity of its treatment.
7
8

9
10 It is increasingly accepted that there is no 'one size fits all' treatment approach for
11 problematic substance use and that a range of treatments are required to meet the
12 diverse needs and preferences of this population.[5 6] For example, effective
13 pharmacological therapies are available to assist with the treatment of some, but not all,
14 substance use disorders (e.g., tobacco, alcohol, opioid dependence).[7] Treatment may
15 also include psychosocial interventions (e.g., cognitive behavioural therapy, contingency
16 management, or strengths-based treatment) either in combination with pharmacological
17 therapies or alone.[8 9] Regardless of the treatment provided, the main goal is to
18 engage clients in care, since treatment engagement is widely recognized as one of the
19 most important predictors of substance use outcomes.[10 11]
20
21
22
23
24
25
26
27
28
29

30 As such, tremendous efforts have been made towards improving treatment
31 engagement. Examples include: diversified treatment settings that offer traditional
32 residential and hospital-based programs, specialized outpatient programs, and more
33 recently, integrated service models.[7 12] To increase the rate of detection and
34 treatment engagement, opportunities for screening and brief intervention have also
35 been incorporated and expanded outside of specialized substance use treatment
36 programs.[13] Various problem-to-services matching designs have also been developed
37 to increase successful treatment engagement by strengthening alignment between
38 client's needs and services offered.[14-17]
39
40
41
42
43
44
45
46
47
48

49 In spite of these important developments, research continues to demonstrate quite
50 mixed uptake of these practices,[17] as well as varying rates of treatment engagement.
51 [7 12] Globally, it is estimated that 1 out of every 6 people in need of substance use
52 treatment is able to receive it; and this does not imply receipt of evidence- or human-
53
54
55
56
57
58

1
2
3
4 rights based treatments.[18] Even when examining evidence-based treatments, such as
5
6 opioid agonist treatment, recent systematic reviews suggest a wide range in the rate of
7
8 treatment retention (e.g., from 37%–91% at 12-month follow-up).[19] There is also a
9
10 substantial body of qualitative research that has revealed several areas in which clients
11
12 (and in some cases providers) have perceived challenges with engaging in treatment. A
13
14 few examples include perceived provider misunderstanding of treatment goals,[20]
15
16 discrepancies between client and provider's treatment goals,[21] a lack of treatment
17
18 responsiveness to client's perceived needs,[22 23] challenges with involving clients in
19
20 treatment planning and delivery,[24] and perceived power imbalances, stigma and
21
22 discrimination.[25-27] This evidence suggests that there remains a need to explore *how*
23
24 treatment processes can be designed to better respond to client's unique needs, while
25
26 also considering the diversity of treatments and settings required.

27
28 Patient-centered care (PCC) is one potential approach warranting further exploration.
29
30 PCC is rooted in a philosophy that *'puts the person first'*. It aims to meet client's unique
31
32 needs and preferences, enhance their experiences with care, and involve them in all
33
34 elements of treatment planning and delivery.[28] Some of its origins can be traced back
35
36 to Carl Rogers' client-centered therapy, which emphasized unconditional positive
37
38 regard, empathy, and genuineness in the therapeutic process.[29] Over the last two
39
40 decades, as the concept of PCC has garnered increased attention across the health
41
42 and social sciences[30 31], its operationalization has expanded beyond the role of the
43
44 therapeutic relationship. For example, in nursing, empirically based conceptual
45
46 frameworks[32-34] agree that PCC entails an approach to care that is holistic,
47
48 individualized, respectful, and empowering. In medicine, the proposed frameworks
49
50 converge around similar, but slightly reframed dimensions. Here, emphasis is on a
51
52 biopsychosocial perspective, seeing the 'patient-as-person', enhancing the therapeutic
53
54
55
56
57
58

1
2
3 alliance, and sharing power and responsibility.[35-40] Differences in the conceptual
4 meaning of PCC across disciplines have resulted in varying operationalizations.
5
6

7
8 That the meaning of PCC is currently somewhat discipline-specific poses challenges to
9 determining the relationship between PCC and treatment process and outcome
10 indicators. For example, a recent meta-analysis showed mixed effects of PCC (defined
11 as shared control or decisions and/or consultations focused on whole person) on
12 improved quality of care, treatment satisfaction and health outcomes.[41] It also found
13 support for generally positive effects of PCC on consultation process measures (e.g.,
14 communication about treatments; levels of empathy),[41] suggesting that PCC might
15 overcome some of the challenges clients have historically experienced engaging in
16 substance use treatment.
17
18
19
20
21
22
23
24
25

26 Indeed, elements of PCC have been recommended or defined as part of some addiction
27 treatment approaches.[6] For example, principles of respect, empathy, or empowerment
28 are integral to some treatments (e.g., motivational interviewing, strengths-based
29 treatment). However, to our knowledge, it is not known to what extent each of the
30 dimensions of PCC have been purposefully implemented or tested across the spectrum
31 of treatment approaches for people with problematic substance use. Bringing this
32 evidence together in a systematic scoping review has the potential to identify cross-
33 setting, discipline and population dimensions of PCC that have been defined,
34 implemented and empirically explored.
35
36
37
38
39
40
41
42
43
44

45 **2. OBJECTIVE**

46
47 The present scoping review will systematically explore how the principles of patient-
48 centered care have been implemented and operationalized in health care settings for
49 people with problematic substance use. Specifically, this review aims to examine the
50 extent and nature of existing evidence of PCC in addiction research and clinical
51 practice.
52
53
54
55
56
57
58

3. METHODS AND ANALYSIS

This scoping review methodology will apply the classic framework developed by Arksey and O'Malley,[42] recent enhancements[43-45] and best practices for conducting and reporting systematic reviews (i.e., Preferred Reporting Items for Systematic Review and Meta-Analysis for Protocols and Scoping Reviews (PRISMA-P and PRISMA-ScR; Supplement 1).[46 47] Accordingly, a reflexive and iterative approach will be maintained; particularly during the study screening and data extraction phases, which may become more refined throughout the review. The protocol (and any potential revisions) has been registered through Open Science Framework (<https://osf.io/5swvd/>).[48] DistillerSR software for systematic reviews[49] will be used by both reviewers to support screening, extraction, monitoring, and the synthesis of findings.

3.1. Stage 1: Defining the Research Question

The research question was developed as a broad framing of the population (i.e., people with problematic substance use), the concept (i.e., patient-centered care) and the context (i.e., health-oriented settings) to be explored. Thus, this scoping review asks:

1. Which patient-centered care principles have been implemented in health-oriented settings for people with problematic substance use?
2. How have these patient-centered care principles been operationalized when used in health-oriented settings for people with problematic substance use?
3. What outcomes from the implementation of patient-centered care principles have been empirically measured or tested?

3.2. Stage 2: Identifying Relevant Literature

Our goal in developing this search strategy (Supplement 2) is to undertake a comprehensive review of the existing evidence base. However, this particular research

1
2
3
4 question poses a challenge to keyword selection due to the evolution of terms used to
5 describe both the population and concept of interest. For instance, problematic
6 substance use has grown from the pejorative language of the 'addict' to a health-
7 oriented view of 'substance dependent populations' and now onto the more person-
8 focused discourse of 'people with problematic substance use'. [50 51]
9
10
11
12

13
14 Likewise, as described above, conceptual frameworks of PCC have also varied, adding
15 to the complexity of this search. To overcome this challenge, we have developed a
16 search strategy informed by the most consistently identified and operationalized
17 principles of PCC (in the abovementioned frameworks), as well as keywords and MeSH
18 terms from systematic reviews [52 53] and empirical references [54-56] previously
19 conducted with our population of interest: (1) *understanding the whole person* to
20 account for the biological, psychological and social aspects of patients' illnesses; (2)
21 *exploring the disease and illness experience* to understand the personal meaning of
22 illness and treatment for the patient; (3) *finding common ground* where power,
23 knowledge and responsibility are shared between the patient and provider; and (4)
24 *enhancing the patient-provider relationship* to improve the positive outcomes of
25 treatments provided. We have also engaged in an extensive consultation process with
26 an experienced Health Science Librarian (at the University of British Columbia) as well
27 as the knowledge users represented in our team (authors SM and SH). The search
28 strategy will also be peer reviewed (i.e., PRESS) to promote its rigor and feasibility. [57]
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 Given our interest in undertaking a comprehensive review of existing research and
46 clinical guidelines related to PCC in the addictions field, both empirical (primary studies,
47 previous reviews) and grey literature documents (conference abstracts, reports, and
48 clinical guidelines) will be included in our search. The search for empirical sources will
49 be conducted in the most important electronic databases for the medical and social
50 sciences: Medline (Ovid), Embase (Ovid), PsycINFO, CINAHL, and ISI Web of Science.
51
52
53
54
55
56
57
58

1
2
3
4 The search strategy has been developed in Medline (Ovid) (Supplement 2) and will be
5 adapted to the other databases. The search strategy will include subject headings,
6 related terms, and keywords as necessary for the research question. Boolean logic and
7 operators (i.e., 'and', 'or', 'not') will be used to combine and refine search terms and
8 concepts.
9
10
11
12

13
14 For the grey literature search strategy, we will use recommended resources[58] and
15 consult with the Health Sciences Librarian and our team's knowledge users to devise a
16 database specific approach. The search for abstracts, reports, and clinical guidelines
17 will be carried out in several Canadian-specific databases: British Columbia Guidelines
18 and Protocols Databases, CPG Infobase, the Registered Nurses' Association Clinical
19 Practice Guidelines Program, and Des Libris. For international grey literature
20 documents, we will search National Guideline Clearinghouse, TRIP, Google, and
21 Google Scholar databases.
22
23
24
25
26
27
28
29

30 **3.3. Stage 3: Study Selection**

31
32 A two-stage collaborative review process will be used to select references. Eligibility
33 criteria have been developed *a priori*, in consultation with the study team. The screening
34 form will be piloted on the first 20 citations of the initial Medline (Ovid) search to test
35 both the criteria and reviewer agreement. Two independent reviewers (authors KM and
36 SB) will apply eligibility criteria during the initial title/abstract review. After each review
37 stage, the reviewer's agreement will be assessed and a third reviewer (author EOJ) will
38 be consulted in cases of disagreement, until consensus is achieved.
39
40
41
42
43
44
45
46

47 A title/abstract (or executive summary for reports and guidelines) will be eligible for full
48 text screening if it:
49
50

51
52 a) Refers to people with problematic substance use (including tobacco, alcohol,
53 cannabis, stimulant, opioid use, or dual diagnoses);
54
55
56
57
58

1
2
3
4 b) Is about delivering patient-centered care or one of its principles (including care that
5 understands the whole person; explores the disease and illness experience; finds
6 common ground and enhances the patient-provider relationship);
7
8

9
10 c) Is set in a health-oriented context (including inpatient or outpatient hospital settings,
11 emergency departments, community-based or primary care health settings, and any
12 specialized drug treatment or low-threshold agencies and programs; excluding prison-
13 based health programs and self-help models such as narcotics or alcoholics
14 anonymous); and
15
16
17
18

19
20 d) Was published between January 1, 1960 and July 1, 2018 in English, French,
21 Spanish, Italian, Portuguese or German.
22
23

24
25 Full text empirical articles, reports and guidelines will then be obtained for
26 titles/abstracts meeting these above criteria and will undergo further screening. In
27 addition to the title/abstract criteria, full texts will be included if:
28
29

30
31 e) It provided an operational definition of the patient-centered care framework that was
32 delivered to people with problematic substance use in the health-oriented context; and
33
34

35
36 f) It observed at least one patient outcome (e.g., treatment engagement, substance use
37 behaviours, treatment satisfaction) and/or treatment process outcome (e.g., provider
38 communication skills) of the patient-centered care approach (this criterion pertains to
39 empirical articles only).
40
41
42
43

44
45 As such, articles that provide only a recommendation to adopt PCC or an opinion of
46 how PCC should be implemented in health-oriented settings for people with problematic
47 substance use will not be included.
48
49

50 51 **3.4. Stage 4: Data Extraction**

52

53
54 Results of the search will be collated in DistillerSR,[49] allowing the research team to
55 de-duplicate and perform data extraction. We will follow recommended data charting
56
57
58

methods[42 47] to systematically capture relevant details for studies/reports and guidelines (Table 1). Data charting forms will be piloted with the first 5 empirical and grey literature references and may be adapted thereafter (with input from the teams' knowledge users).

Table 1. Data extraction and charting for empirical and grey literature sources

Domain/Subdomain	Description
1. General Document Details	
1.1 Reference Type	Empirical study, case study, review, commentary, report, guideline
1.2 Publication Year	Year of publication
1.3 Country and Location	Country of publication (and location if provided)
1.4 Publication Language	Language of publication
2. Empirical Study References (if applicable)	
2.1 Research objective	What was the research objective or specific question to be tested (if relevant)
2.2 Study design	Was the study design observational, experimental, or qualitative?
2.3 Study population	What were the eligibility criteria? Would the population be classified as primarily: tobacco, cannabis, alcohol, opioid, stimulant, or comorbid substance use and mental illness?
2.4 Patient-centered care intervention	What was the operational definition of patient-centered care used (including the definition of specific principles, if available)? How long was the intervention provided or observed for?
2.5 Context/setting	What health-oriented context was the PCC intervention apart of? What health professionals were involved?

2.6 Study outcomes	For quantitative studies, what types of patient outcomes and/or process outcomes were measured (e.g., treatment engagement, changes in substance use behaviours, health status, treatment satisfaction, provider communication)? For qualitative studies, what outcomes were described?
2.7 Important results	What were the main results of the study? Were there any important sub-group (e.g., by sex and gender, by primary substance, by health care provider) analyses?
2.8 Limitations	What limitations did the authors describe? What others might there be?
3. Grey Literature References (if applicable)	
3.1 Target audience	Is there a target audience specified for the guideline/report (e.g., policy/decision maker, health care provider, patient/client/family)
3.2 Reference population	If available, how was the target patient population defined? Any specific eligibility criteria used? Would the population be classified as primarily: tobacco, cannabis, alcohol, opioid, stimulant, or comorbid substance use and mental illness?
3.3 Patient-centered care operational definition	What was the operational definition of patient-centered care used (including the definition of specific principles, if available)?
3.4 Context/setting	What health-oriented context was the PCC intervention apart of? What health professionals were involved?
3.5 Intervention and outcomes	If applicable, was a specific patient-centered intervention described (e.g., a training module, a clinical approach)?

	Were any patient outcomes and/or process outcomes of PCC reported (e.g., treatment engagement, substance use outcomes, treatment satisfaction, provider communication)?
3.6 Program evaluation	If available, what results were reported from any ongoing program evaluations?

3.5. Stage 5: Collating, Summarizing and Reporting the Results

We will present a descriptive overview (including tabular and/or graphical summaries) of the eligible full texts.[42] We will also summarize studies by each broader category of substances primarily used (i.e., tobacco, cannabis, alcohol, opioid, stimulant, dual diagnosis). Displaying information in this way will highlight population-specific similarities and differences in PCC, its definition and outcomes. This will facilitate the identification of future directions for research and practice. All tables and charts will include narrative summaries, relating the findings to the review's research question. Additionally, we will develop a final report of the review[47] according to PRISMA-ScR guidelines.[46]

Given that one aim of this review is to understand *how* PCC has been defined and implemented in health care services for people with problematic substance use, a directed content analysis will be carried out on included guidelines. This approach has been deemed most suitable to the present review, since it allows existing theory (in our case, principles of PCC defined a priori to guide the coding and analysis), while still allowing new evidence to emerge.[59] Specifically, we are interested in qualitatively analyzing the definition of PCC adopted in the guidelines, how it was developed, which health care providers were involved, and any outcomes or ongoing evaluations of the program. To do so, data from the guidelines will be imported to MAXQDA, version 12,[60] a qualitative analysis software program that supports a multi-user approach.

1
2
3
4 This analysis will be conducted by authors KM, SB, and EOJ, who have prior
5
6 experience conducting thematic analysis on similar topics.[61 62] As is common in
7
8 directed content qualitative analysis,[59] a coding framework will be developed a priori,
9
10 and will then be applied by authors KM and SB independently. Results from this
11
12 analysis will be summarized and—where relevant—numerical summaries may also be
13
14 used to provide additional context to the themes (e.g., number of clients treated,
15
16 number of staff).

17 18 **3.6. Stage 6: Consultation Process and Engagement of Knowledge Users**

19
20 The ultimate aim of this review is to generate evidence that can be used to inform
21
22 decision-makers and health care providers on the feasibility, implications, and potential
23
24 outcomes associated with PCC for substance use treatment. To achieve this goal, we
25
26 have engaged a multi-disciplinary team of knowledge users who represent the needs of:
27
28 people with problematic substance use, health care providers, and decision makers.
29
30 Consulting with the teams' health care providers and decision-makers (authors SH, SM,
31
32 and DCM) will promote a methodology that reflects the realities of patient-provider roles
33
34 and the health care system's organization. Also, our team's drug policy knowledge user
35
36 (author JW) represents a national organization of people who use drugs and this critical
37
38 perspective will ensure that all aspects of this review are rooted in the client-centered
39
40 needs of this diverse population. The specific contributions of the Knowledge Users to
41
42 each stage of this review have been defined throughout. At this time, Knowledge Users
43
44 have reviewed early drafts of the search strategy, identifying additional terms that are
45
46 important for inclusion given the population, concept, and contexts of interest (e.g.,
47
48 trauma-informed care and culturally-safe care). Knowledge Users have also provided
49
50 several grey-literature references (clinical guidelines and reports) to be considered for
51
52 inclusion. As the project continues to evolve, all Knowledge Users will be involved in
53
54 supporting the interpretation of findings and their dissemination.
55
56
57
58

3.7 PATIENT AND PUBLIC INVOLVEMENT

This scoping review protocol has engaged the expertise of a national organization of people who use(d) drugs through the involvement of this organizations' President. This knowledge user (author JW) has made contributions to the development of the research question and will also be extensively involved during the interpretation and dissemination phases of this project.

4. ETHICS AND DISSEMINATION

As substance use disorders are increasingly recognized as a chronic condition often marked by cycles of relapse and recovery, the public health care system is considering how existing treatment and intervention approaches can be optimized to meet the long-term and evolving goals of clients.[18] Adopting patient- or person-centered approaches may increase the responsiveness of existing treatments to individual client needs, expectations, and preferences. To our knowledge, this review will be the first to systematically examine the extent and nature of existing evidence of PCC in addiction research and clinical practice.

Our dissemination strategy will utilize traditional approaches, including open-access peer-reviewed publication(s), scientific presentations, and a report. Additionally, we are committed to promoting further action based on the potential findings of this review. Therefore, we will host a half-day roundtable meeting—bringing together people with problematic substance use, health care providers (from diverse settings), and decision-makers to brainstorm potential opportunities for future areas of research and clinical practice work. For example, we may engage in a concept mapping exercise, using the findings of this review to integrate stakeholders' knowledge, interpretations, and

1
2
3
4 priorities into practice. The multidisciplinary nature of this team will facilitate and support
5
6 our goal of bringing together these different representatives together.
7
8
9

10 **AUTHOR CONTRIBUTIONS:**

11
12 KM (review guarantor) led the design and conceptualisation of this review and drafted the
13 protocol with primary support from SB, MTS, and EOJ. SB, SH, and EOJ were involved in
14 refining the search strategy, including key words. SM, SH, DCM, and JW were involved in
15 establishing eligibility criteria and data extraction forms. All authors provided feedback on the
16 manuscript and approval to the publishing of this protocol manuscript.
17
18

19
20 **AMENDMENTS:** Not applicable
21

22
23 **SUPPORT (SOURCES, SPONSOR, ROLE OF SPONSOR OR FUNDER):** Funding for this
24 scoping review has been provided by the Canadian Institutes of Health Research (Operating
25 Grant: Opioid Crisis Knowledge Synthesis). We would also like to acknowledge Ursula Ellis,
26 Health Sciences Librarian (University of British Columbia), who has provided invaluable
27 expertise to the development and refinement of the search strategy of this scoping review.
28
29

30
31 **COMPETING INTERESTS:** The authors have no competing interests to declare.
32
33
34
35

36 **References**

- 37
38
39 1. Gakidou E, Afshin A, Abajobir AA, et al. Global, regional, and national comparative risk
40 assessment of 84 behavioural, environmental and occupational, and metabolic risks or
41 clusters of risks, 1990-2016: A systematic analysis for the Global Burden of Disease Study
42 2016. *The Lancet* 2017;390(10100):1345-422. doi: 10.1016/S0140-6736(17)32366-8
43
44 2. Holford TR, Meza R, Warner KE, et al. Tobacco control and the reduction in smoking-
45 related premature deaths in the united states, 1964-2012. *JAMA* 2014;311(2):164-71. doi:
46 10.1001/jama.2013.285112
47
48 3. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to
49 mental and substance use disorders: findings from the Global Burden of Disease Study
50 2010. *Lancet* 2013;382(9904):1575-86. doi: 10.1016/s0140-6736(13)61611-6 [published
51 Online First: 2013/09/03]
52
53 4. Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis.
54 *Lancet* 2010;376(9752):1558-65. doi: [http://dx.doi.org/10.1016/S0140-6736\(10\)61462-6](http://dx.doi.org/10.1016/S0140-6736(10)61462-6)
55
56
57
58

- 1
2
3 5. Hammer G. Trust and relationship as cornerstones of successful psychotherapy. In:
4 Tatarsky A, Tatarsky A, eds. Harm reduction psychotherapy: A new treatment for drug and
5 alcohol problems. Lanham, MD, US: Jason Aronson 2002:106-35.
- 6
7 6. Abou-Saleh MT, Tarter RE, Salloum IM. Substance use disorders. In: Mezzich JE, Botbol M,
8 Christodoulou GN, et al., eds. Person centered psychiatry. Cham, Switzerland: Springer
9 International Publishing 2016:325-43.
- 10
11 7. Substance Abuse and Mental Health Services Administration. Chapter 4, Early
12 Intervention, Treatment, And Management of Substance Use Disorders. In: Office of the
13 Surgeon General (US), ed. Facing Addiction in America: The Surgeon General's Report on
14 Alcohol, Drugs, and Health. Washington (DC), 2016.
- 15
16 8. Jhanjee S. Evidence Based Psychosocial Interventions in Substance Use. *Indian Journal of*
17 *Psychological Medicine* 2014;36(2):112-18. doi: 10.4103/0253-7176.130960
- 18
19 9. Magill M, Ray LA. Cognitive-Behavioral Treatment With Adult Alcohol and Illicit Drug
20 Users: A Meta-Analysis of Randomized Controlled Trials. *Journal of Studies on Alcohol and*
21 *Drugs* 2009;70(4):516-27. doi: 10.15288/jsad.2009.70.516
- 22
23 10. Hubbard RL, Craddock SG, Flynn PM, et al. Overview of One-Year Follow-Up Outcomes
24 in the Drug Abuse Treatment Outcome Study (DATOS). *Psychology of Addictive Behaviors*
25 1997;11(4 special issue):261-78.
- 26
27 11. Simpson DD, Joe GW, Rowan-Szal GA. Drug abuse treatment retention and process
28 effects on follow-up outcomes. *Drug Alcohol Depend* 1997;47(3):227-35.
- 29
30 12. Substance Abuse and Mental Health Services Administration. Chapter 6, Health Care
31 Systems and Substance Use Disorders. In: US Department of Health and Human Services,
32 ed. Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and
33 Health Washington (DC)2016.
- 34
35 13. Babor TF, McRee BG, Kassebaum PA, et al. Screening, Brief Intervention, and Referral to
36 Treatment (SBIRT). *Substance Abuse* 2007;28(3):7-30. doi: 10.1300/J465v28n03_03
- 37
38 14. Marsh JC, Cao D, Shin HC. Closing the Need-Service Gap: Gender Differences in Matching
39 Services to Client Needs in Comprehensive Substance Abuse Treatment. *Social work*
40 *research* 2009;33(3):183-92. [published Online First: 2009/09/01]
- 41
42 15. Hser YI, Polinsky ML, Maglione M, et al. Matching clients' needs with drug treatment
43 services. *J Subst Abuse Treat* 1999;16(4):299-305. [published Online First: 1999/06/01]
- 44
45 16. Mattson ME, Babor, T, Cooney, N, et al. Matching patients with alcohol disorders to
46 treatments: Clinical implications from Project MATCH. *Journal of Mental Health*
47 1998;7(6):589-602. doi: 10.1080/09638239817743
- 48
49 17. Alexander JA, Nahra TA, Lemak CH, et al. Tailored treatment in the outpatient substance
50 abuse treatment sector: 1995-2005. *Journal of Substance Abuse Treatment* 2008;34(3):282-
51 92.
- 52
53 18. United Nations Office on Drugs and Crime. International Standards for the Treatment of
54 Drug Use Disorders. Geneva: World Health Organization, 2017.

- 1
2
3 19. Timko C, Schultz NR, Cucciare MA, et al. Retention in medication-assisted treatment for
4 opiate dependence: A systematic review. *J Addict Dis* 2016;35(1):22-35. doi:
5 10.1080/10550887.2016.1100960 [published Online First: 2015/10/16]
6
7 20. Rance J, Treloar C. "We are people too": consumer participation and the potential
8 transformation of therapeutic relations within drug treatment. *International Journal of*
9 *Drug Policy* 2015;26(1):30-36. doi: 10.1016/j.drugpo.2014.05.002
10
11 21. Joosten EAG, De Weert-Van Oene GH, Sensky T, et al. Treatment goals in addiction
12 healthcare: The perspectives of patients and clinicians. *International Journal of Social*
13 *Psychiatry* 2011;57(3):263-76. doi: 10.1177/0020764009354835
14
15 22. McNeil R, Kerr T, Pauly B, et al. Advancing patient-centered care for structurally
16 vulnerable drug-using populations: A qualitative study of the perspectives of people who
17 use drugs regarding the potential integration of harm reduction interventions into
18 hospitals. *Addiction* 2016;111(4):685-94. doi: 10.1111/add.13214
19
20 23. Pauly B, McCall J, Browne AJ, et al. Toward cultural safety: Nurse and patient
21 perceptions of illicit substance use in a hospitalized setting. *Advances in Nursing Science*
22 2015;38(2):121-35. doi: 10.1097/ANS.0000000000000070
23
24 24. Bryant J, Bryant J, Saxton M, et al. Consumers' and providers' perspectives about
25 consumer participation in drug treatment services: is there support to do more? What are
26 the obstacles? *Drug and Alcohol Review* 2008;27(2):138-44. doi:
27 10.1080/09595230701829405
28
29 25. Fischer J, Neale J. Involving drug users in treatment decisions: An exploration of
30 potential problems. *Drugs: Education, Prevention & Policy* 2008;15(2):161-75. doi:
31 10.1080/09687630701391604
32
33 26. Strike C, Rufo C. Embarrassing, degrading, or beneficial: patient and staff perspectives
34 on urine drug testing in methadone maintenance treatment. *Journal of Substance Use*
35 2010;15(5):303-12. doi: 10.3109/14659890903431603
36
37 27. Palis H, Marchand K, Peng D, et al. Factors Associated with Perceived Abuse in the
38 Health Care System Among Long-Term Opioid Users: A Cross-Sectional Study. *Subst Use*
39 *Misuse* 2016;51(6):763-76. doi: 10.3109/10826084.2016.1155605 [published Online First:
40 2016/04/21]
41
42 28. Berwick DM. What 'patient-centered' should mean: confessions of an extremist. *Health*
43 *Aff (Millwood)* 2009;28(4):w555-65. doi: 10.1377/hlthaff.28.4.w555 [published Online
44 First: 2009/05/21]
45
46 29. Rogers C. On Becoming a Person. A Therapist's View of Psychotherapy. Boston:
47 Houghton Mifflin Company 1961.
48
49 30. Institute of Medicine (IOM). Crossing the Quality Chasm: A New Health System for the
50 21st Century. 2001.
51
52 31. Beaulieu MD. President's message: toward a patient-centred health care system. *Can*
53 *Fam Physician* 2013;59(1):109,10. [published Online First: 2013/01/24]
54
55
56
57
58

- 1
2
3 32. Slater L. Person-centredness: a concept analysis. *Contemp Nurse* 2006;23(1):135-44.
4 doi: 10.5555/conu.2006.23.1.135 [published Online First: 2006/11/07]
5
- 6 33. Hobbs JL. A dimensional analysis of patient-centered care. *Nurs Res* 2009;58(1):52-62.
7 doi: 10.1097/NNR.0b013e31818c3e79 [published Online First: 2008/12/19]
8
- 9 34. Morgan S, Yoder LH. A concept analysis of person-centered care. *J Holist Nurs*
10 2012;30(1):6-15. doi: 10.1177/0898010111412189 [published Online First: 2011/07/21]
11
- 12 35. Mead N, Bower P. Patient-centredness: a conceptual framework and review of the
13 empirical literature. *Soc Sci Med* 2000;51(7):1087-110. [published Online First:
14 2000/09/27]
15
- 16 36. Stewart M. Towards a global definition of patient centred care. *BMJ*
17 2001;322(7284):444-5. [published Online First: 2001/02/27]
18
- 19 37. Robinson JH, Callister LC, Berry JA, et al. Patient-centered care and adherence:
20 definitions and applications to improve outcomes. *J Am Acad Nurse Pract* 2008;20(12):600-
21 7. doi: 10.1111/j.1745-7599.2008.00360.x [published Online First: 2009/01/06]
22
- 23 38. McMillan SS, Kendall E, Sav A, et al. Patient-centered approaches to health care: a
24 systematic review of randomized controlled trials. *Medical care research and review : MCRR*
25 2013;70(6):567-96. doi: 10.1177/1077558713496318 [published Online First:
26 2013/07/31]
27
- 28 39. Scholl I, Zill JM, Harter M, et al. An integrative model of patient-centeredness - a
29 systematic review and concept analysis. *PLoS One* 2014;9(9):e107828. doi:
30 10.1371/journal.pone.0107828 [published Online First: 2014/09/18]
31
- 32 40. Santana MJ, Manalili K, Jolley RJ, et al. How to practice person-centred care: A
33 conceptual framework. *Health Expectations : An International Journal of Public Participation*
34 *in Health Care and Health Policy* 2018;21(2):429-40. doi: 10.1111/hex.12640
35
- 36 41. Dwamena F, Holmes-Rovner M, Gaulden CM, et al. Interventions for providers to
37 promote a patient-centred approach in clinical consultations. *Cochrane Database Syst Rev*
38 2012;12:CD003267. doi: 10.1002/14651858.CD003267.pub2 [published Online First:
39 2012/12/14]
40
- 41 42. Arksey H, O'Malley L. Scoping studies: towards a methodological framework.
42 *International Journal of Social Research Methodology* 2005;8(1):19-32. doi:
43 10.1080/1364557032000119616
44
- 45 43. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology.
46 *Implementation Science* 2010;5(1):69. doi: 10.1186/1748-5908-5-69
47
- 48 44. Daudt HM, van Mossel C, Scott SJ. Enhancing the scoping study methodology: a large,
49 inter-professional team's experience with Arksey and O'Malley's framework. *BMC Medical*
50 *Research Methodology* 2013;13(1):48. doi: 10.1186/1471-2288-13-48
51
- 52 45. Colquhoun HL, Levac D, O'Brien KK, et al. Scoping reviews: time for clarity in definition,
53 methods, and reporting. *J Clin Epidemiol* 2014;67(12):1291-4. doi:
54 10.1016/j.jclinepi.2014.03.013 [published Online First: 2014/07/19]
55
56
57
58

- 1
2
3 46. Tricco AC, Lillie E, Zarin W, et al. Prisma extension for scoping reviews (PRISMA-ScR):
4 Checklist and explanation. *Annals of Internal Medicine* 2018 doi: 10.7326/M18-0850
5
- 6 47. Joanna Briggs Institute. The Joanna Briggs Institute Reviewers' Manual 2015:
7 Methodology for JBI Scoping Reviews. Australia, 2015.
8
- 9 48. Center for Open Science. Open Science Framework Charlottesville, VA2011 [cited 2018].
10 Available from: <https://osf.io> accessed 07-MAY-2018.
11
- 12 49. DistillerSR: Systematic Review and Literature Review Software [program]. Ottawa,
13 Canada: Evidence Partners, 2016.
14
- 15 50. Kelly JF, Saitz R, Wakeman S. Language, Substance Use Disorders, and Policy: The Need
16 to Reach Consensus on an "Addiction-ary". *Alcoholism Treatment Quarterly*
17 2016;34(1):116-23. doi: 10.1080/07347324.2016.1113103
18
- 19 51. Broyles LM, Binswanger IA, Jenkins JA, et al. Confronting inadvertent stigma and
20 pejorative language in addiction scholarship: a recognition and response. *Subst Abuse*
21 2014;35(3):217-21. doi: 10.1080/08897077.2014.930372 [published Online First:
22 2014/06/10]
23
- 24 52. Barrio P, Gual A. Patient-centered care interventions for the management of alcohol use
25 disorders: a systematic review of randomized controlled trials. *Patient Prefer Adherence*
26 2016;10:1823-45. doi: 10.2147/ppa.s109641 [published Online First: 2016/10/04]
27
- 28 53. Friedrichs A, Spies M, Härter M, et al. Patient preferences and Shared Decision Making
29 in the treatment of substance use disorders: A systematic review of the literature. *PLoS*
30 *ONE* 2016;11(1)
31
- 32 54. Schwartz RP, Kelly SM, Mitchell SG, et al. Patient-centered methadone treatment: a
33 randomized clinical trial. *Addiction* 2017;112(3):454-64. doi: 10.1111/add.13622
34
- 35 55. Joosten E, de Weert G, Sensky T, et al. Effect of shared decision-making on therapeutic
36 alliance in addiction health care. *Patient Prefer Adherence* 2008;2:277-85. [published
37 Online First: 2008/01/01]
38
- 39 56. Joosten EAG, De Weert-Van Oene GH, Sensky T, et al. Treatment Goals in Addiction
40 Healthcare: the Perspectives of Patients and Clinicians. *International Journal of Social*
41 *Psychiatry* 2010;57(3):263-76. doi: 10.1177/0020764009354835
42
- 43 57. McGowan J, Sampson M, Salzwedel DM, et al. PRESS Peer Review of Electronic Search
44 Strategies: 2015 Guideline Statement. *J Clin Epidemiol* 2016;75:40-6. doi:
45 10.1016/j.jclinepi.2016.01.021 [published Online First: 2016/03/24]
46
- 47 58. Canadian Agency for Drugs and Technologies in Health. Grey Matters: a practical tool
48 for searching health-related grey literature. 2015 [Available from:
49 <https://www.cadth.ca/resources/finding-evidence/grey-matters> accessed November 22,
50 2017.
51
- 52 59. Hsieh H-F, Shannon SE. Three Approaches to Qualitative Content Analysis. *Qualitative*
53 *Health Research* 2005;15(9):1277-88. doi: 10.1177/1049732305276687
54
- 55 60. MAXQDA. Qualitative Analysis Software [program], 2015.
56
57
58

1
2
3 61. Oviedo-Joekes E, Marchand K, Palis H, et al. Predictors of treatment allocation guesses
4 in a randomized controlled trial testing double-blind injectable hydromorphone and
5 diacetylmorphine for severe opioid use disorder. *Addiction Research & Theory*
6 2017;25(4):263-72. doi: 10.1080/16066359.2016.1263729
7

8 62. Oviedo-Joekes E, Marchand K, Lock K, et al. A chance to stop and breathe: participants'
9 experiences in the North American Opiate Medication Initiative clinical trial. *Addiction*
10 *science & clinical practice* 2014;9:21-31. doi: 10.1186/1940-0640-9-21 [published Online
11 First: 2014/09/30]
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

For peer review only

PRISMA-P Checklist

		Reporting Item	Page Number
10	Identification	#1a Identify the report as a protocol of a systematic review	1
13	Update	#1b If the protocol is for an update of a previous systematic review, identify as such	NA
17		#2 If registered, provide the name of the registry (such as PROSPERO) and registration number	2
21	Contact	#3a Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
26	Contribution	#3b Describe contributions of protocol authors and identify the guarantor of the review	10
31		#4 If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	NA
37	Sources	#5a Indicate sources of financial or other support for the review	10
40	Sponsor	#5b Provide name for the review funder and / or sponsor	10
42	Role of sponsor or funder	#5c Describe roles of funder(s), sponsor(s), and / or institution(s), if any, in developing the protocol	10
46	Rationale	#6 Describe the rationale for the review in the context of what is already known	3-4
50	Objectives	#7 Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	4-5
55	Eligibility criteria	#8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be	6-7

used as criteria for eligibility for the review

1				
2				
3	Information	#9	Describe all intended information sources (such as	5-6
4	sources		electronic databases, contact with study authors, trial	
5			registers or other grey literature sources) with planned	
6			dates of coverage	
7				
8				
9				
10	Search strategy	#10	Present draft of search strategy to be used for at least one	Supplement
11			electronic database, including planned limits, such that it	2
12			could be repeated	
13				
14				
15	Study records -	#11a	Describe the mechanism(s) that will be used to manage	4
16	data management		records and data throughout the review	
17				
18				
19	Study records -	#11b	State the process that will be used for selecting studies	6
20	selection process		(such as two independent reviewers) through each phase	
21			of the review (that is, screening, eligibility and inclusion in	
22			meta-analysis)	
23				
24				
25				
26	Study records -	#11c	Describe planned method of extracting data from reports	7
27	data collection		(such as piloting forms, done independently, in duplicate),	
28	process		any processes for obtaining and confirming data from	
29			investigators	
30				
31				
32				
33	Data items	#12	List and define all variables for which data will be sought	7-8
34			(such as PICO items, funding sources), any pre-planned	
35			data assumptions and simplifications	
36				
37				
38				
39	Outcomes and	#13	List and define all outcomes for which data will be sought,	7
40	prioritization		including prioritization of main and additional outcomes,	
41			with rationale	
42				
43				
44	Risk of bias in	#14	Describe anticipated methods for assessing risk of bias of	See note 1
45	individual studies		individual studies, including whether this will be done at the	
46			outcome or study level, or both; state how this information	
47			will be used in data synthesis	
48				
49				
50				
51	Data synthesis	#15a	Describe criteria under which study data will be	8-9
52			quantitatively synthesised	
53				
54				
55		#15b	If data are appropriate for quantitative synthesis, describe	8-9
56			planned summary measures, methods of handling data and	
57			methods of combining data from studies, including any	
58				
59				
60				

planned exploration of consistency (such as I², Kendall's τ)

#15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) 8-9

#15d If quantitative synthesis is not appropriate, describe the type of summary planned 8-9

Meta-bias(es) #16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) See note 2

Confidence in cumulative evidence #17 Describe how the strength of the body of evidence will be assessed (such as GRADE) See note 3

Author notes

1. NA for scoping review
2. NA for scoping reviews
3. NA for scoping reviews

The PRISMA-P checklist is distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. This checklist was completed on 02. June 2018 using <http://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)

Table 1. Medline (Ovid) search strategy

Search term/line number	Conceptual term of interest	Search term entered into Ovid-Medline	Number of hits
1	Substance-Related Disorders	exp Substance-Related Disorders	258462
2	Street Drugs	exp Street Drugs	11263
3	Substance abuser	substance abus*	49532
4	Substance dependent	substance dependen*	2720
5	Substance misuse	substance misus*	2150
6	Problematic substance use	Problematic substance adj2 (use* or usage or using)	254
7	People who inject drugs	(people who inject drug* or PWID)	1740
8	Injection drug use	injection drug "(use or user or usage or using)" or IDU	2794
9	People who use drugs	"people who use drugs" or PWUD	343
10	Illicit substance use	(illicit or street or illegal) adj2 (drug or substance) adj2 (use* or usage or using)	5848
11	opioid dependence	opioid adj2 (addict* or abus* or dependen* or misus* or problem* or disorder*)	15537
12	opiate dependence	opiate adj2 (addict* or abus* or dependen* or misus* or problem* or disorder*)	3475
13	narcotic dependence	narcotic adj2 (addict* or abus* or dependen* or misus* or problem* or disorder*)	1279
14	heroin	heroin	17865
15	stimulant use disorder	"stimulant use disorder"	40

16	exp crack cocaine	exp crack cocaine	1343
17	exp cocaine smoking	exp cocaine smoking	4
18	cocaine dependence	((cocaine or crack) adj2 (addict* or abus* or dependen* or misus* or problem* or disorder*))	11806
19	amphetamine dependence	(amphetamine or crystal methamphetamine or crystal meth) adj1 (addict* or abus* or dependen* or misus* or problem* or disorder*)	592
20	alcohol dependence	alcohol adj2 (addict* or abus* or dependen* or misus* or problem* or disorder*)	50104
21	cannabis dependence	cannabis adj2 (addict* or abus* or dependen* or disorder*)	1917
22	tobacco dependence	(tobacco or nicotine or smok*) adj2 (dependen* or disorder* or cessation)	45598
23	Diagnosis, Dual (Psychiatry)	Diagnosis, Dual (Psychiatry)	3372
24		1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23	337412
25	exp Patient-Centered Care	exp Patient-Centered Care	16653
26	Patient centered care	((patient or client or person) adj1 cent?red adj1 (care or treatment* or therap*))	20713
27	Patient focused care	((patient or client or person) adj1 focus?ed adj1 (care or treatment* or therap*))	425
28	Patient participation in treatment planning, process, decisions	(patient or client) adj1 (autonom* or involve* or control or empower*) adj1 (decision making or care or practic* or treatment* or plan*)	126
29	Collaborative care	collaborative adj1 (care or practic* or treatment* or plan*)	3803
30	Shared decision-making	(shared or joint or collaborative) adj2 decision making	6279
31	Therapeutic alliance	therapeutic alliance	9027
32	Relational practice	relational practic*	44

33	Enhanced patient-provider relationship	(physician or doctor or nurse or professional or provider) adj1 (patient or client) adj1 (enhanc* or alliance* or empower* or support*)	304
34	Enhanced patient-provider communication	(physician or doctor or nurse or professional or provider) adj1 (patient or client) adj1 communicat*	4230
35	Holistic Nursing	Holistic Nursing/	3135
36	Trauma informed care	trauma adj1 (cent?red or informed) adj1 (care or approach or treatment* or therap*)	263
37	Culturally safe care	cultural* adj1 (safe or sensitive) adj1 (care or approach or treatment* or therap*)	395
39	Family Systems Nursing	Family Systems Nursing	64
39	Expert patient program	expert patient program*	27
40		25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39	40281
41		24 and 40	896

Update and Run Date: June 27, 2018